| Urinary tract stone occurrence in the Women's Health Initiative (WHI) randomized clinical trial of calcium and vitamin D supplements 2011 · CaD group · Postmenopausal women aged 50–79 years | 1 g | 400 IU | 7 years | 18,176 |
| Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study 2013 · Calcium plus vitamin D (CaD) group · Postmenopausal women aged 50–79 years | 1 g | 400 IU | 7 years | 18,176 |
| A Randomized Trial of Calcium Plus Vitamin D Supplementation and Risk of Ductal Carcinoma In Situ of the Breast 2021 · calcium plus vitamin D · Postmenopausal women aged 50–79 years at enrollment | 1 g | 400 IU | 2592 days | 18,176 |
| Incidence of hematologic malignancy and cause-specific mortality in the Women's Health Initiative randomized controlled trial of calcium and vitamin D supplementation 2017 · active treatment · older women; median age 63 years | 1 g | 400 IU | 7 years | 18,141 |
| Risk of heart failure among postmenopausal women: a secondary analysis of the randomized trial of vitamin D plus calcium of the women's health initiative 2015 · intervention group · Postmenopausal women aged 50–79 years, free of heart failure at baseline, with and without pre-existing cardiovascular risk conditions | 1 g | 400 IU | 2577 days | 18,023 |
| Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study 2004 · Calcium and Vitamin D Program · Community-dwelling residents aged 66 years and older | 1 g | 400 IU | 3 years | 4,957 |
| Effect of Vitamin D and Calcium Supplementation on Cancer Incidence in Older Women: A Randomized Clinical Trial 2017 · vitamin D3 + calcium group · Healthy postmenopausal women aged 55 years or older | 1.5 g | 2,000 IU | 1461 days | 1,156 |
| Zoledronic acid and clinical fractures and mortality after hip fracture 2007 · zoledronic acid group · Men and women aged 50 years or older after surgical repair of a recent minimal-trauma hip fracture | 1 g | 800 IU | 1826 days | 1,065 |
| Zoledronic acid and clinical fractures and mortality after hip fracture 2007 · placebo group · Men and women aged 50 years or older after surgical repair of a recent minimal-trauma hip fracture | 1 g | 800 IU | 1826 days | 1,062 |
| Multivitamin and mineral supplementation is associated with the reduction of fracture risk and hospitalization rate in Chinese adult males: a randomized controlled study 2015 · supplement group — women · Women aged 40–69 with esophageal squamous dysplasia (ESD) in Linxian, China | 324 mg | 20 mcg | 6 years | 927 |
| Multivitamin and mineral supplementation is associated with the reduction of fracture risk and hospitalization rate in Chinese adult males: a randomized controlled study 2015 · supplement group — men · Men aged 40–69 with esophageal squamous dysplasia (ESD) in Linxian, China | 324 mg | 20 mcg | 6 years | 726 |
| Prevention of benign paroxysmal positional vertigo with vitamin D supplementation: A randomized trial 2020 · intervention · Patients with confirmed benign paroxysmal positional vertigo (BPPV); supplementation was given when serum vitamin D was below 20 ng/mL | 1 g | 800 IU | 1 year | 518 |
| Calcium and vitamin D supplementation and increased risk of serrated polyps: results from a randomised clinical trial 2019 · calcium and vitamin D · Adults aged 45–75 with at least one adenomatous polyp detected and removed within the preceding 4 months | 1.2 g | 1,000 IU | 5 years | 421 |
| A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group 2000 · 200-IU salmon calcitonin group · Postmenopausal women with established osteoporosis | 1 g | 400 IU | 5 years | 287 |
| A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group 2000 · Placebo group · Postmenopausal women with established osteoporosis | 1 g | 400 IU | 5 years | 270 |
| Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study 2009 · Risedronate group · Men with primary or secondary osteoporosis | 1 g | 800 IU | 2 years | 158 |
| Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy 1998 · Placebo (Ca-D group) · Postmenopausal women with osteoporosis and vertebral fractures | 1 g | 800 IU | 2 years | 146 |
| Comprehensive Interventions Including Vitamin D Effectively Reduce the Risk of Falls in Elderly Osteoporotic Patients 2021 · A VitD group · Adults over 60 years with osteoporosis (BMD at or below −2.5), recurrent osteoporosis-related pain; mean age about 71 years, predominantly women | 800 mg | 0.5 mcg | 1 year | 99 |
| Comprehensive Interventions Including Vitamin D Effectively Reduce the Risk of Falls in Elderly Osteoporotic Patients 2021 · NA VitD group · Adults over 60 years with osteoporosis (BMD at or below −2.5), recurrent osteoporosis-related pain; mean age about 71 years, predominantly women | 800 mg | 800 IU | 1 year | 98 |
| Comprehensive Interventions Including Vitamin D Effectively Reduce the Risk of Falls in Elderly Osteoporotic Patients 2021 · P-A VitD group · Adults over 60 years with osteoporosis (BMD at or below −2.5), recurrent osteoporosis-related pain; mean age about 72 years, predominantly women | 800 mg | 0.5 mcg | 1 year | 98 |
| Comprehensive Interventions Including Vitamin D Effectively Reduce the Risk of Falls in Elderly Osteoporotic Patients 2021 · P-NA VitD group · Adults over 60 years with osteoporosis (BMD at or below −2.5), recurrent osteoporosis-related pain; mean age about 70 years, predominantly women | 800 mg | 800 IU | 1 year | 97 |
| The efficacy of vitamin D combined with clomiphene citrate in ovulation induction in overweight women with polycystic ovary syndrome: a double blind, randomized clinical trial 2020 · Vitamin D with calcium · Overweight subfertile women with PCOS undergoing ovulation induction | 2.5 g | — | — | 93 |
| Randomized clinical trial of intraoperative parathyroid gland angiography with indocyanine green fluorescence predicting parathyroid function after thyroid surgery 2018 · Control group · Adults undergoing total or completion thyroidectomy with at least one well-perfused parathyroid gland identified by indocyanine green angiography; men and women; thyroid disease requiring surgery | 2 g | 1,600 IU | 15 days | 73 |
| Perioperative versus postoperative calcium and vitamin D supplementation to prevent symptomatic hypocalcemia after total thyroidectomy: a randomized placebo controlled trial 2023 · Perioperative supplementation group · Adults older than 18 years undergoing total or completion thyroidectomy | 4.5 g | 1 mcg | 17 days | 68 |
| Perioperative versus postoperative calcium and vitamin D supplementation to prevent symptomatic hypocalcemia after total thyroidectomy: a randomized placebo controlled trial 2023 · Postoperative supplementation group · Adults older than 18 years undergoing total or completion thyroidectomy | 4.5 g | 1 mcg | 2 weeks | 66 |
| Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial 2003 · Cal+D-group · Elderly women aged 63–99 years in long-stay geriatric care | 1.2 g | 800 IU | 12 weeks | 62 |
| Fall Prevention and Anti-Osteoporosis in Osteopenia Patients of 80 Years of Age and Older: A Randomized Controlled Study 2020 · experiment group · Men and women aged 80–93 years with osteopenia living independently | 600 mg | 125 IU | 548 days | 62 |
| Fall Prevention and Anti-Osteoporosis in Osteopenia Patients of 80 Years of Age and Older: A Randomized Controlled Study 2020 · control group · Men and women aged 80–93 years with osteopenia living independently | 600 mg | 125 IU | 548 days | 61 |
| Prevention of postoperative hypocalcemia with routine oral calcium and vitamin D supplements in patients with differentiated papillary thyroid carcinoma undergoing total thyroidectomy plus central neck dissection 2009 · Group A · Patients with differentiated papillary thyroid carcinoma undergoing total thyroidectomy plus central neck dissection; age and sex not specified | 3 g | 1 mg | — | 49 |
| Routine oral calcium and vitamin D supplements for prevention of hypocalcemia after total thyroidectomy 2006 · oral calcium/vitamin D group · patients who underwent total thyroidectomy; age and sex not specified | 3 g | 1 g | 2 weeks | 45 |
| Does Preoperative Calcium and Calcitriol Decrease Rates of Post-Thyroidectomy Hypocalcemia? A Randomized Clinical Trial 2021 · Control group · Patients undergoing total thyroidectomy; age and sex not reported | 4.5 g | 0.5 mcg | — | 44 |
| [Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia] 2014 · VD group · Men with idiopathic oligoasthenozoospermia | 600 mg | 200 IU | 90 days | 43 |
| Does Preoperative Calcium and Calcitriol Decrease Rates of Post-Thyroidectomy Hypocalcemia? A Randomized Clinical Trial 2021 · Intervention group · Patients undergoing total thyroidectomy; age and sex not reported | 4.5 g | 0.5 mcg | — | 38 |
| Is fall prevention by vitamin D mediated by a change in postural or dynamic balance? 2006 · Vitamin D plus calcium · Institutionalized women aged 65–97 | 1.2 g | 800 IU | 90 days | 33 |
| Vitamin D reduces musculoskeletal pain after infusion of zoledronic acid for postmenopausal osteoporosis 2012 · Cholecalciferol group · Postmenopausal women with osteoporosis | 1 g | 300,800 IU | 7 days | 30 |
| Vitamin D reduces musculoskeletal pain after infusion of zoledronic acid for postmenopausal osteoporosis 2012 · Placebo group with shared supplementation · Postmenopausal women with osteoporosis | 1 g | 800 IU | 7 days | 30 |
| Calcium plus vitamin D supplementation affects pregnancy outcomes in gestational diabetes: randomized, double-blind, placebo-controlled trial 2016 · Ca+vitamin D group · Pregnant women with gestational diabetes mellitus (GDM) in Arak, Iran | 1 g | — | 6 weeks | 30 |
| The efficacy of oral vitamin D supplements on fusion outcome in patients receiving elective lumbar spinal fusion-a randomized control trial 2022 · Experimental group · Adults aged 20–80 undergoing elective lumbar spinal fusion for spinal stenosis or degenerative spondylolisthesis | 600 mg | 800 IU | 90 days | 21 |
| A comparison of calcium, vitamin D, or both for nutritional rickets in Nigerian children 1999 · combination-therapy group · Nigerian children with nutritional rickets; median age 46 months | 1 g | — | 24 weeks | — |
| Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group 2000 · risedronate 2.5 mg/day group · postmenopausal women with two or more prevalent vertebral fractures and established osteoporosis | 1 g | 500 IU | 2 years | — |
| Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group 2000 · risedronate 5 mg/day group · postmenopausal women with two or more prevalent vertebral fractures and established osteoporosis | 1 g | 500 IU | 3 years | — |
| Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group 2000 · placebo group · postmenopausal women with two or more prevalent vertebral fractures and established osteoporosis | 1 g | 500 IU | 3 years | — |
| A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group 2000 · 100-IU salmon calcitonin group · Postmenopausal women with established osteoporosis | 1 g | 400 IU | 5 years | — |
| A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group 2000 · 400-IU salmon calcitonin group · Postmenopausal women with established osteoporosis | 1 g | 400 IU | 5 years | — |
| Varying role of vitamin D deficiency in the etiology of rickets in young children vs. adolescents in northern India 2003 · Calcium with vitamin D · Children with rickets and adolescents with rickets/osteomalacia | 1 g | — | 23 weeks | — |
| The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial 2005 · risedronate group · Elderly women with Alzheimer disease and baseline 25-hydroxyvitamin D deficiency | 1.2 g | 1,000 IU | 548 days | — |
| The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial 2005 · control group · Elderly women with Alzheimer disease and baseline 25-hydroxyvitamin D deficiency | 1.2 g | 1,000 IU | 548 days | — |
| Should older people in residential care receive vitamin D to prevent falls? Results of a randomized trial 2005 · Vitamin D supplementation group · Older residents of residential care, mean age 83.4 years, with serum 25-hydroxyvitamin D levels of 25–90 nmol/L | 600 mg | — | 2 years | — |
| Effect of cholecalciferol plus calcium on falling in ambulatory older men and women: a 3-year randomized controlled trial 2006 · cholecalciferol-calcium · Ambulatory, community-dwelling men and women aged 65 years or older | 500 mg | 700 IU | 3 years | — |
| Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial 2007 · PTH group · Postmenopausal women with osteoporosis and low bone mineral density at the hip or lumbar spine | 700 mg | — | 548 days | — |
| Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial 2007 · Ca + D · Healthy postmenopausal women aged over 55 years | 1.4 g | 1,100 IU | 4 years | — |
| Interaction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: reanalysis of Women's Health Initiative randomized trial 2008 · calcium plus vitamin-D supplementation · Women in the Women's Health Initiative; age and specific health conditions are not stated in the abstract | 1 g | 400 IU | — | — |
| Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women 2008 · ergocalciferol group · Community-dwelling women aged 70–90 with serum 25-hydroxyvitamin D below 24.0 ng/mL and a history of falling in the previous year | 1 g | 1,000 IU | 1 year | — |
| Additive benefit of higher testosterone levels and vitamin D plus calcium supplementation in regard to fall risk reduction among older men and women 2008 · vitamin D3 plus calcium · Community-dwelling, healthy ambulatory men and women aged 65 years or older | 500 mg | 700 IU | 3 years | — |
| Calcium and vitamin d supplementation decreases incidence of stress fractures in female navy recruits 2008 · calcium and vitamin D group · female Navy recruits undergoing basic training | 2 g | 800 IU | 8 weeks | — |
| Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals 2009 · calcium plus vitamin D · Community-dwelling women and men, mean age 77 years, with serum 25-hydroxyvitamin D below 78 nmol/l | 1 g | 800 IU | 1 year | — |
| Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study 2009 · Control group without previous vertebral fractures · Men with primary or secondary osteoporosis without previous vertebral fractures | 1.2 g | 800 IU | 2 years | — |
| Calcium plus vitamin D supplementation and mortality in postmenopausal women: the Women's Health Initiative calcium-vitamin D randomized controlled trial 2009 · CaD supplementation · Postmenopausal women aged 51–82 years | 1 g | 400 IU | 2557 days | — |
| Calcium plus vitamin D supplementation and the risk of nonmelanoma and melanoma skin cancer: post hoc analyses of the women's health initiative randomized controlled trial 2011 · CaD (calcium plus vitamin D) · Postmenopausal women aged 50 to 79 years enrolled in the Women's Health Initiative calcium/vitamin D trial | 1 g | 400 IU | 7 years | — |
| Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set 2011 · Calcium and vitamin D (CaD) · Community-dwelling postmenopausal women | 1 g | 400 IU | 2557 days | — |
| Women's Health Initiative clinical trials: interaction of calcium and vitamin D with hormone therapy 2014 · Active CaD + active hormone therapy · Postmenopausal women aged 50–79; not selected for low bone density or osteoporosis | 1 g | 400 IU | 2628 days | — |
| Women's Health Initiative clinical trials: interaction of calcium and vitamin D with hormone therapy 2014 · Active CaD + placebo hormone therapy · Postmenopausal women aged 50–79; not selected for low bone density or osteoporosis | 1 g | 400 IU | 2628 days | — |
| Risk of hypercalcemia in blacks taking hydrochlorothiazide and vitamin D 2014 · 1000 IU vitamin D group · Black or African-American adults aged 30–80 years in a healthy community-based population; the reported safety analysis included participants taking HCTZ | 200 mg | 1,000 IU | 90 days | — |
| Risk of hypercalcemia in blacks taking hydrochlorothiazide and vitamin D 2014 · 2000 IU vitamin D group · Black or African-American adults aged 30–80 years in a healthy community-based population; the reported safety analysis included participants taking HCTZ | 200 mg | 2,000 IU | 90 days | — |
| Risk of hypercalcemia in blacks taking hydrochlorothiazide and vitamin D 2014 · 4000 IU vitamin D group · Black or African-American adults aged 30–80 years in a healthy community-based population; the reported safety analysis included participants taking HCTZ | 200 mg | 4,000 IU | 90 days | — |
| The effect of calcium plus vitamin D supplementation on the risk of venous thromboembolism. From the Women's Health Initiative Randomized Controlled Trial 2015 · calcium and vitamin D group · Postmenopausal women aged 50–79 years | 1 g | 400 IU | 7 years | — |
| Age of menopause and fracture risk in postmenopausal women randomized to calcium + vitamin D, hormone therapy, or the combination: results from the Women's Health Initiative Clinical Trials 2017 · Ca/D intervention · Postmenopausal women aged 50–79 with an intact uterus, included in the analytical sample by self-reported age of natural menopause | 1 g | 400 IU | — | — |
| Age of menopause and fracture risk in postmenopausal women randomized to calcium + vitamin D, hormone therapy, or the combination: results from the Women's Health Initiative Clinical Trials 2017 · HT + Ca/D intervention · Postmenopausal women aged 50–79 with an intact uterus, included in the analytical sample by self-reported age of natural menopause | 1 g | 400 IU | — | — |
| Vitamin D Receptor Genotype, Vitamin D3 Supplementation, and Risk of Colorectal Adenomas: A Randomized Clinical Trial 2017 · Vitamin D3 plus calcium · Adults aged 45–75 with at least one large-bowel adenoma removed before enrollment | 1.2 g | 1,000 IU | 1376 days | — |
| The influence of genetic susceptibility and calcium plus vitamin D supplementation on fracture risk 2017 · calcium plus vitamin D group · White postmenopausal women | 1 g | 400 IU | 339 weeks | — |
| Women's Health Initiative clinical trials: potential interactive effect of calcium and vitamin D supplementation with hormonal therapy on cardiovascular disease 2019 · CaD-supplement group · Postmenopausal women in the Women's Health Initiative who entered the calcium and vitamin D trial after one year in a menopausal hormone therapy trial | 1 g | 400 IU | 2264 days | — |
| Risk of keratinocyte carcinomas with vitamin D and calcium supplementation: a secondary analysis of a randomized clinical trial 2020 · Vitamin D3 plus calcium carbonate · Men and women aged 45–75 recently diagnosed with a colorectal adenoma | 1.2 g | 1,000 IU | 5 years | — |
| Impact of Common Vitamin D-Binding Protein Isoforms on Supplemental Vitamin D3 and/or Calcium Effects on Colorectal Adenoma Recurrence Risk: A Secondary Analysis of a Randomized Clinical Trial 2023 · Vitamin D3 and calcium · Adults with a recently diagnosed colorectal adenoma and no remaining polyps after complete colonoscopy; the analyzed subgroup consisted of non-Hispanic White participants | 1.2 g | 1,000 IU | 5 years | — |
| Long-Term Effect of Randomization to Calcium and Vitamin D Supplementation on Health in Older Women : Postintervention Follow-up of a Randomized Clinical Trial 2024 · CaD · Postmenopausal women with no history of breast or colorectal cancer | 1 g | 400 IU | 7 years | — |
| Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy 1998 · Sodium fluoride · Postmenopausal women with osteoporosis and vertebral fractures | 1 g | 800 IU | 2 years | — |
| Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy 1998 · Monofluorophosphate, 200 mg/day · Postmenopausal women with osteoporosis and vertebral fractures | 1 g | 800 IU | 2 years | — |
| Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy 1998 · Monofluorophosphate, 150 mg/day · Postmenopausal women with osteoporosis and vertebral fractures | 1 g | 800 IU | 2 years | — |
| Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: Randomized, controlled, double-blind trial 2017 · calcium carbonate + calcitriol · Patients with non-alcoholic fatty liver disease (NAFLD) following an energy-restricted weight-loss program; age and sex not stated | 500 mg | 25 mcg | 12 weeks | 37 |
| Overweight postmenopausal women lose bone with moderate weight reduction and 1 g/day calcium intake 2005 · WL NL-Ca · Overweight postmenopausal women aged 50–75 undergoing weight loss | 400 mg | 400 IU | 180 days | 22 |
| Overweight postmenopausal women lose bone with moderate weight reduction and 1 g/day calcium intake 2005 · WM NL-Ca · Overweight postmenopausal women aged 50–75 assigned to weight maintenance | 400 mg | 400 IU | 180 days | 18 |
| Calcium plus vitamin D supplementation has limited effects on femoral geometric strength in older postmenopausal women: the Women's Health Initiative 2011 · CaD group · Postmenopausal women aged 50–79 years | 1 g | — | 5 years | 1,179 |
| Effects of Enhanced Exercise and Combined Vitamin D and Calcium Supplementation on Muscle Strength and Fracture Risk in Postmenopausal Chinese Women 2017 · group C · Postmenopausal women at high risk of osteoporosis | 600 mg | — | 2 years | 139 |
| Effects of Enhanced Exercise and Combined Vitamin D and Calcium Supplementation on Muscle Strength and Fracture Risk in Postmenopausal Chinese Women 2017 · group D · Postmenopausal women at high risk of osteoporosis | 600 mg | 0.25 mcg | 2 years | 131 |
| An initial loading-dose vitamin D versus placebo after hip fracture surgery: randomized trial 2016 · Active · Adults aged 65 years or older who had undergone hip fracture surgery; men and women with a recent surgically repaired hip fracture | 500 mg | 800 IU | 26 weeks | 111 |
| Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial 2016 · denosumab 60 mg Q6M · Japanese adults aged 20–74 with rheumatoid arthritis on methotrexate | 600 mg | 400 IU | 1 year | 85 |
| Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial 2016 · denosumab 60 mg Q2M · Japanese adults aged 20–74 with rheumatoid arthritis on methotrexate | 600 mg | 400 IU | 1 year | 85 |
| Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial 2016 · denosumab 60 mg Q3M · Japanese adults aged 20–74 with rheumatoid arthritis on methotrexate | 600 mg | 400 IU | 1 year | 82 |
| Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial 2017 · Placebo arm · Women with stage I–III breast cancer starting adjuvant letrozole, with 25(OH)D level ≤40 ng/ml; median age 61 | 1.2 g | 600 IU | 24 weeks | 80 |
| Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial 2017 · Vitamin D3 arm · Women with stage I–III breast cancer starting adjuvant letrozole, with 25(OH)D level ≤40 ng/ml; median age 61 | 1.2 g | 4,886 IU | 24 weeks | 80 |
| High-intensity aquatic exercises (HydrOS) improve physical function and reduce falls among postmenopausal women 2013 · aquatic exercise group (AEG) · Postmenopausal women, mean age 58.8 years | 500 mg | 1,000 IU | 24 weeks | 64 |
| Effects of vitamin D and/or calcium intervention on sleep quality in individuals with prediabetes: a post hoc analysis of a randomized controlled trial 2024 · vitamin D + calcium group · Chinese individuals with prediabetes; age and sex not specified | 500 mg | 1,600 IU | 24 weeks | 53 |
| Combination of alfacalcidol and calcium improved handgrip strength and mobility among Indonesian older women: A randomized controlled trial 2018 · Alfacalcidol group · Indonesian older women with handgrip strength ≤22 kg | 500 mg | 0.5 mcg | 90 days | 47 |
| High-intensity aquatic exercises (HydrOS) improve physical function and reduce falls among postmenopausal women 2013 · control group (CG) · Postmenopausal women, mean age 58.8 years | 500 mg | 1,000 IU | 24 weeks | 44 |
| Vitamin D treatment in calcium-deficiency rickets: a randomised controlled trial 2014 · Ca+D group · Children older than 1 year with active calcium-deficiency rickets | 1.88 g | — | 24 weeks | 44 |
| A Nutritionally Complete Oral Nutritional Supplement Powder Improved Nutritional Outcomes in Free-Living Adults at Risk of Malnutrition: A Randomized Controlled Trial 2022 · nutrition supplement (intervention group) · Chinese men and women aged 18 years or older, all classified as at risk of malnutrition; mean age 66.5 years, range 41–89 | 400 mg | 8 mcg | 12 weeks | 44 |
| Effect of vitamin D(3) and calcium carbonate supplementation on muscle strength in postmenopausal women living with HIV 2020 · Low VitD group · Postmenopausal African American or Hispanic women aged 40–70 living with HIV, with serum 25-OHD of 10–32 ng/ml and stable antiretroviral therapy | 1 g | 1,000 IU | 1 year | 41 |
| Effect of vitamin D(3) and calcium carbonate supplementation on muscle strength in postmenopausal women living with HIV 2020 · Moderate VitD group · Postmenopausal African American or Hispanic women aged 40–70 living with HIV, with serum 25-OHD of 10–32 ng/ml and stable antiretroviral therapy | 1 g | 3,000 IU | 1 year | 41 |
| Changes in body composition following a dietary and lifestyle intervention trial: the postmenopausal health study 2009 · dietary intervention group (DG) · Healthy postmenopausal women | 1.2 g | 7.5 mcg | 1 year | 39 |
| Effects of combined calcium and vitamin D supplementation on insulin secretion, insulin sensitivity and β-cell function in multi-ethnic vitamin D-deficient adults at risk for type 2 diabetes: a pilot randomized, placebo-controlled trial 2014 · combined calcium and vitamin D treatment · Multi-ethnic men and women aged 18 years or older, vitamin D-deficient and at risk of type 2 diabetes; BMI 25–40 kg/m² | 1.2 g | 2,000 IU | 26 weeks | 35 |
| A randomized controlled trial of high dose vitamin D3 in patients with heart failure 2013 · Vitamin D3 group · Adults aged 50 years or older with heart failure (NYHA class II–IV) and serum 25OHD ≤37.5 ng/ml | 800 mg | 7,143 IU | 26 weeks | 32 |
| Calcium Plus Vitamin D Supplementation During the Third Trimester of Pregnancy in Adolescents Accustomed to Low Calcium Diets Does Not Affect Infant Bone Mass at Early Lactation in a Randomized Controlled Trial 2015 · calcium plus vitamin D supplementation · Brazilian adolescent mothers consuming low-calcium diets, from 26 weeks of gestation until parturition | 600 mg | 200 IU | — | 30 |
| Calcium plus vitamin D supplementation during pregnancy reduces postpartum fat mass in adolescents: A randomized trial 2023 · calcium plus vitamin D supplement · Brazilian pregnant adolescents aged 14–19 years with habitually low calcium intake | 600 mg | — | — | 30 |
| The use of bone turnover markers for monitoring the treatment of osteoporosis in postmenopausal females undergoing total knee arthroplasty: a prospective randomized study 2021 · control group · Postmenopausal women aged 55–75 with osteoporosis and osteoarthritis undergoing total knee arthroplasty | 300 mg | — | 90 days | 29 |
| The use of bone turnover markers for monitoring the treatment of osteoporosis in postmenopausal females undergoing total knee arthroplasty: a prospective randomized study 2021 · monitoring group · Postmenopausal women aged 55–75 with osteoporosis and osteoarthritis undergoing total knee arthroplasty | 300 mg | — | 214 days | 28 |
| The effect of vitamin D and calcium supplementation on inflammatory biomarkers, estradiol levels and severity of symptoms in women with postpartum depression: a randomized double-blind clinical trial 2022 · Vitamin D3 + calcium carbonate · Women with postpartum depression and a PPD score >12 | 500 mg | — | 8 weeks | 27 |
| Calcium plus vitamin D3 supplementation facilitated fat loss in overweight and obese college students with very-low calcium consumption: a randomized controlled trial 2013 · calcium+D group · Generally healthy overweight or obese college students aged 18–25 years with daily calcium intake below 600 mg; predominantly female | 600 mg | 125 IU | 12 weeks | 26 |
| The effects of calcium-vitamin D and metformin on polycystic ovary syndrome: a pilot study 2009 · Group 1 · Infertile women with polycystic ovary syndrome (PCOS); age not stated | 1 g | 400 IU | 90 days | 20 |
| The effects of calcium-vitamin D and metformin on polycystic ovary syndrome: a pilot study 2009 · Group 2 · Infertile women with polycystic ovary syndrome (PCOS); age not stated | 1 g | 400 IU | 90 days | 20 |
| Effect of cholecalciferol and calcium supplementation on muscle strength and energy metabolism in vitamin D-deficient Asian Indians: a randomized, controlled trial 2010 · Cholecalciferol and calcium supplementation · Healthy adults with hypovitaminosis D; mean age 31.5 years; 24 men and 16 women across both groups | 1 g | — | 26 weeks | 20 |
| Effects of Vitamin D and Calcium Fortified Yogurts on Gait, Cognitive Performances, and Serum 25-Hydroxyvitamin D Concentrations in Older Community-Dwelling Females: Results from the GAit, MEmory, Dietary and Vitamin D (GAME-D2) Randomized Controlled Trial 2019 · intervention group (fortified yogurt) · Females aged 65 years or older with hypovitaminosis D (serum 25OHD <75 nmol/L), living independently at home or in an autonomous residence | 800 mg | 400 IU | 90 days | 20 |
| The acute effects of milk intake on calcium homeostasis and cardiovascular outcome: A randomized crossover trial in postmenopausal women 2022 · 500 ml semi-skimmed milk with added cholecalciferol · Postmenopausal women aged 60–80 years with vitamin D insufficiency at screening | 619 mg | 200 mcg | 1 day | 20 |
| Predicting the need for calcium and calcitriol supplementation after total thyroidectomy: results of a prospective, randomized study 2012 · Group B (calcium and calcitriol; PTH <5) · Adults aged 18–82 undergoing completion or total thyroidectomy, with POD1 PTH <5 | 3 g | 1 mcg | 15 days | 7 |
| Is routine supplementation therapy (calcium and vitamin D) useful after total thyroidectomy? 2002 · group C · Patients who underwent total thyroidectomy | 3 g | 1 mg | 26 weeks | — |
| Effects of vitamin D supplementation and exercise training on physical performance in Chilean vitamin D deficient elderly subjects 2006 · resistance training plus vitamin D and calcium · Adults aged 70 years or older with 25-hydroxyvitamin D levels of 16 ng/mL or less; described as healthy elderly subjects | 800 mg | 400 IU | 270 days | — |
| Effects of vitamin D supplementation and exercise training on physical performance in Chilean vitamin D deficient elderly subjects 2006 · control (no resistance training) plus vitamin D and calcium · Adults aged 70 years or older with 25-hydroxyvitamin D levels of 16 ng/mL or less; described as healthy elderly subjects | 800 mg | 400 IU | 270 days | — |
| Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis 2007 · RE+ (reinforcement) · Postmenopausal women aged 65–80 with osteoporosis or a low-trauma fracture | 500 mg | 400 IU | 1 year | — |
| Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis 2007 · RE− (no reinforcement) · Postmenopausal women aged 65–80 with osteoporosis or a low-trauma fracture | 500 mg | 400 IU | 1 year | — |
| Calcium plus vitamin D supplementation and the risk of postmenopausal weight gain 2007 · calcium plus cholecalciferol · Postmenopausal women aged 50 to 79 years | 1 g | 400 IU | 7 years | — |
| Predictors of adherence in the Women's Health Initiative Calcium and Vitamin D Trial 2009 · active treatment · Postmenopausal women aged 50–79 years | 1 g | 400 IU | — | — |
| Calcium plus vitamin D supplementation and fat mass loss in female very low-calcium consumers: potential link with a calcium-specific appetite control 2009 · calcium+D supplementation · Overweight or obese women, mean age 43 years, with daily calcium intake below 800 mg | 1.2 g | 10 mcg | 15 weeks | — |
| A comparison between the efficacy of dydrogesterone and calcium plus vitamin D in improving women's general health 2010 · calcium plus vitamin D · Young women who were students at Shiraz University | 1 g | 400 mg | — | — |
| A randomized controlled trial of the effects of vitamin D on muscle strength and mobility in older women with vitamin D insufficiency 2010 · Vitamin D group · Women aged 70 to 90 with vitamin D insufficiency, living in the community | 1 g | 1,000 IU | 1 year | — |
| A pilot randomized controlled trial of oral calcium and vitamin D supplementation using fortified laddoos in underprivileged Indian toddlers 2011 · study group · Underprivileged toddlers, mean age 2.7 years; most were hypocalcaemic and vitamin D deficient | 405 mg | — | 1 year | — |
| Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial 2011 · Vitamin D and calcium group · Adults at high risk of type 2 diabetes; mean age 57 years | 800 mg | 2,000 IU | 16 weeks | — |
| Calcium and vitamin D supplementation is associated with decreased abdominal visceral adipose tissue in overweight and obese adults 2012 · Calcium and vitamin D-fortified regular orange juice · Overweight and obese adults; mean age 40.0 ± 12.9 years; sex not stated | 1.05 g | 300 IU | 16 weeks | — |
| Calcium and vitamin D supplementation is associated with decreased abdominal visceral adipose tissue in overweight and obese adults 2012 · Calcium and vitamin D-fortified lite orange juice · Overweight and obese adults; mean age 40.0 ± 12.9 years; sex not stated | 1.05 g | 300 IU | 16 weeks | — |
| School-based calcium-vitamin D with micronutrient supplementation enhances bone mass in underprivileged Indian premenarchal girls 2012 · Ca-group · Premenarchal girls aged 8–12 years from low-income groups in Pune, India | 500 mg | — | 1 year | — |
| Skeletal muscle strength in young Asian Indian females after vitamin D and calcium supplementation: a double-blind randomized controlled clinical trial 2012 · cholecalciferol/calcium · young adult Asian Indian females with vitamin D deficiency; mean age 21.7 years | 1 g | — | 26 weeks | — |
| Vitamin D3 supplementation and upper respiratory tract infections in a randomized, controlled trial 2013 · vitamin D(3) plus calcium · Adults aged 45–75 in good health, with a history of colorectal adenoma and serum 25-hydroxyvitamin D ≥12 ng/mL | 1.2 g | 1,000 IU | — | — |
| Effect of micronutrient supplementation on height velocity of underprivileged girls in comparison with un-supplemented healthy controls 2014 · Ca+D group (C2) · Underprivileged premenarchal girls aged 8–12 years | 500 mg | — | 1 year | — |
| Effect of treatment of vitamin D deficiency and insufficiency during pregnancy on fetal growth indices and maternal weight gain: a randomized clinical trial 2014 · control group · Pregnant women at 24–26 weeks of gestation with vitamin D deficiency or insufficiency | 200 mg | — | 8 weeks | — |
| Effects of Calcium Plus Vitamin D Supplementation on Anthropometric Measurements and Blood Pressure in Vitamin D Insufficient People with Type 2 Diabetes: A Randomized Controlled Clinical Trial 2015 · 50,000 IU/wk vitamin D3 plus 1000 mg/d calcium · People with type 2 diabetes and vitamin D insufficiency | 1 g | 7,143 IU | 8 weeks | — |
| A phase IV, two-armed, randomized, cross-over study comparing compliance with once-a-month administration of vitamin D3 to compliance with daily administration of a fixed-dose combination of vitamin D3 and calcium during two 6-month periods 2015 · VDCa group · Adult male and female volunteers aged 50 years or older | 1 g | 800 IU | 26 weeks | — |
| Effects of Calcium-Vitamin D and Calcium-Alone on Pain Intensity and Menstrual Blood Loss in Women with Primary Dysmenorrhea: A Randomized Controlled Trial 2017 · calcium-vitamin D group · Women students with moderate or severe primary dysmenorrhea | 1 g | 5,000 IU | — | — |
| Calcium plus vitamin D supplementation and height loss: findings from the Women's Health Initiative Calcium and Vitamin D clinical trial 2016 · CaD group · Postmenopausal women aged 50–79, generally healthy | 1 g | 400 IU | 8 years | — |
| High dose vitamin D may improve lower urinary tract symptoms in postmenopausal women 2017 · high dose group · Postmenopausal women with low bone mineral density | 1 g | — | 1 year | — |
| High dose vitamin D may improve lower urinary tract symptoms in postmenopausal women 2017 · standard dose group · Postmenopausal women with low bone mineral density | 1 g | 800 IU | 1 year | — |
| Vitamin D and Calcium Milk Fortification in Pregnant Women with Periodontitis: A Feasibility Trial 2020 · Group 1—fortified milk and early therapy · Pregnant women aged 18 years or older with low-risk pregnancy and periodontitis | 1 g | 1,000 IU | — | — |
| Vitamin D and Calcium Milk Fortification in Pregnant Women with Periodontitis: A Feasibility Trial 2020 · Group 3—fortified milk and late therapy · Pregnant women aged 18 years or older with low-risk pregnancy and periodontitis | 1 g | 1,000 IU | — | — |
| Calcium Carbonate Attenuates Withdrawal and Reduces Craving: A Randomized Controlled Trial in Alcohol-Dependent Patients 2021 · calcium carbonate group · Alcohol-dependent patients undergoing inpatient alcohol-withdrawal treatment; age and sex not specified | 800 mg | 5 mcg | 2 weeks | — |
| Exploratory Efficacy of Calcium-Vitamin D Milk Fortification and Periodontal Therapy on Maternal Oral Health and Metabolic and Inflammatory Profile 2021 · Fortified sachet and powdered milk plus periodontal treatment during pregnancy (early PT + fortification) · Adult pregnant women with periodontitis; age over 18 years, enrolled by up to 20 weeks’ gestation | 1 g | 1,000 IU | — | — |
| Exploratory Efficacy of Calcium-Vitamin D Milk Fortification and Periodontal Therapy on Maternal Oral Health and Metabolic and Inflammatory Profile 2021 · Fortified sachet and powdered milk plus periodontal treatment after delivery (late PT + fortification) · Adult pregnant women with periodontitis; age over 18 years, enrolled by up to 20 weeks’ gestation | 1 g | 1,000 IU | — | — |
| Daily intake of yogurt drink fortified either with vitamin D alone or in combination with added calcium causes a thyroid-independent increase of resting metabolic rate in adults with type 2 diabetes: a randomized, double-blind, clinical trial 2021 · Ca-D-fortified yogurt drink (CDY) · Adults with type 2 diabetes | 500 mg | 1,000 IU | 12 weeks | — |
| Effects of vitamin D on sex steroids, luteinizing hormone, and testosterone to luteinizing hormone ratio in 307 infertile men 2024 · active group · infertile men | 500 mg | 301,400 IU | 150 days | — |
| Effect of Calcium and Vitamin D Supplementation (Dairy vs. Pharmacological) on Bone Health of Underprivileged Indian Children and Youth with Type-1 Diabetes: A Randomized Controlled Trial 2024 · Calcium supplement (group B) · Underprivileged Indian children and youth aged 5–23 years with type-1 diabetes mellitus; both sexes | 500 mg | 1,000 IU | 1 year | — |
| Alcohol use disorder and muscle weakness: Original study of the effect of vitamin D supplementation in ambulatory participants with alcohol use disorder 2024 · CAU (care as usual) · Community-dwelling adults with alcohol use disorder; ages and sex by arm not reported. The reported outcome subgroup had vitamin D concentrations below 50 nmol/L. | 500 mg | 800 IU | 1 year | — |
| Effect of cholecalciferol supplementation on hand grip strength, walking speed, and expression of vitamin D receptor, interleukin-6, and insulin-like growth factor-1 in monocyte in pre-frail older adults: A randomized double-blind placebo-controlled trial 2024 · cholecalciferol group · pre-frail older adults | 500 mg | 4,000 IU | 12 weeks | — |
| Effects of Vitamin D3 Treatment on Polycystic Ovary Symptoms: A Prospective Double-Blind Two-Phase Randomized Controlled Clinical Trial 2025 · D12 · Premenopausal women aged 18 or older with PCOS and serum 25(OH)D of 10–30 ng/mL | 400 mg | 4,286 IU | 12 weeks | — |
| Effects of Vitamin D3 Treatment on Polycystic Ovary Symptoms: A Prospective Double-Blind Two-Phase Randomized Controlled Clinical Trial 2025 · D24 · Premenopausal women aged 18 or older with PCOS and serum 25(OH)D of 10–30 ng/mL | 400 mg | 4,286 IU | 24 weeks | — |
| Phosphate concentration is exceptionally high in seminal fluid and is linked with semen quality but not influenced by vitamin D and calcium supplementation 2025 · vitamin D and calcium supplementation · infertile men; age range and sex beyond male not specified | 500 mg | — | 150 days | — |
| Treatment of postmenopausal osteoporosis with recombinant human parathyroid hormone and electromagnetic field 2025 · Group A (PEMF and rhPTH) · Postmenopausal women with osteoporosis; mean age 65.21 years | 600 mg | — | 548 days | 115 |
| Treatment of postmenopausal osteoporosis with recombinant human parathyroid hormone and electromagnetic field 2025 · Group B (rhPTH) · Postmenopausal women with osteoporosis; mean age 65.23 years | 600 mg | — | 548 days | 113 |
| Treatment of postmenopausal osteoporosis with recombinant human parathyroid hormone and electromagnetic field 2025 · Group C (PEMF) · Postmenopausal women with osteoporosis; mean age 65.37 years | 600 mg | — | 548 days | 108 |
| A smartphone application to improve adherence to vitamin and mineral supplementation after bariatric surgery 2022 · Intervention group · Adults aged over 18 to 60 years undergoing gastric bypass or sleeve gastrectomy | 1 g | — | 1 year | 71 |
| A smartphone application to improve adherence to vitamin and mineral supplementation after bariatric surgery 2022 · Control group · Adults aged over 18 to 60 years undergoing gastric bypass or sleeve gastrectomy | 1 g | — | 1 year | 69 |
| Leucine-Enriched Protein Supplementation Increases Lean Body Mass in Healthy Korean Adults Aged 50 Years and Older: A Randomized, Double-Blind, Placebo-Controlled Trial 2020 · protein mixture powder (intervention group) · Healthy Korean adults aged 50–80 years, men and women, without sarcopenia | 600 mg | 1,600 IU | 12 weeks | 54 |
| The effect of 12-weeks Nutritional supplementation on Nutritional Intake and Status among Indonesian Older Outpatients with Malnutrition Risk, the Prolansia study: a randomized controlled trial 2025 · intervention group (standard care plus NDD) · Men and women aged 60 years and older with malnutrition or at risk of malnutrition, attending outpatient clinics in Indonesia | 500 mg | 800 IU | 12 weeks | 54 |
| Soy isoflavones, lactobacilli, Magnolia bark extract, vitamin D3 and calcium. Controlled clinical study in menopause 2006 · ES (Estromineral serena) · Symptomatic menopausal women with sleep or mood alterations | 141 mg | — | 24 weeks | 44 |
| Beneficial effects of exercise, testosterone, vitamin D, calcium and protein in older men-A randomized clinical trial 2024 · combo group · Men aged 70 years or older with low-normal to low testosterone and mobility impairment | 800 mg | 38 mcg | 16 weeks | 36 |
| Beneficial effects of exercise, testosterone, vitamin D, calcium and protein in older men-A randomized clinical trial 2024 · training group · Men aged 70 years or older with low-normal to low testosterone and mobility impairment | 800 mg | 38 mcg | 16 weeks | 36 |
| Magnesium-Zinc-Calcium-Vitamin D Co-supplementation Improves Hormonal Profiles, Biomarkers of Inflammation and Oxidative Stress in Women with Polycystic Ovary Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial 2018 · Magnesium-zinc-calcium-vitamin D co-supplementation · Women with polycystic ovary syndrome (PCOS); age not reported | 800 mg | 400 IU | 12 weeks | 30 |
| A whey protein-based multi-ingredient nutritional supplement stimulates gains in lean body mass and strength in healthy older men: A randomized controlled trial 2017 · SUPP (multi-ingredient nutritional supplement) · Healthy men aged 60 years or older | 800 mg | 1,000 IU | 20 weeks | 25 |
| A prospective randomized comparative trial evaluating postoperative nutritional intervention in patients with oral cancer 2022 · Intervention group · Adults with oral cancer after surgery; ages 18 and older, both sexes | 1 g | 2,857 IU | 26 weeks | 22 |
| Obesity and Metabolic Disease Impair the Anabolic Response to Protein Supplementation and Resistance Exercise: A Retrospective Analysis of a Randomized Clinical Trial with Implications for Aging, Sarcopenic Obesity, and Weight Management 2024 · Muscle 5 (M5) · Men aged 66–91 years; older, sedentary or low-active participants, with the subgroup analysis including overweight or obese men with at least one additional metabolic-syndrome risk factor | 416 mg | 1,000 IU | 12 weeks | 16 |
| The Effect of a Multi-ingredient Supplement on Resistance Training-induced Adaptations 2021 · SUPP group · Healthy young adults, male and female, mean age 22 ± 2 years, undertaking resistance exercise training | 600 mg | 2,000 IU | 10 weeks | 13 |
| School-based calcium-vitamin D with micronutrient supplementation enhances bone mass in underprivileged Indian premenarchal girls 2012 · Ca+MZ-group · Premenarchal girls aged 8–12 years from low-income groups in Pune, India | 500 mg | — | 1 year | — |
| Effect of micronutrient supplementation on height velocity of underprivileged girls in comparison with un-supplemented healthy controls 2014 · Ca+MZn+D group (C1) · Underprivileged premenarchal girls aged 8–12 years | 500 mg | — | 1 year | — |
| Effect of treatment of vitamin D deficiency and insufficiency during pregnancy on fetal growth indices and maternal weight gain: a randomized clinical trial 2014 · intervention group · Pregnant women at 24–26 weeks of gestation with vitamin D deficiency or insufficiency | 200 mg | — | 8 weeks | — |
| Vitamin D insufficiency does not affect bone mineral density response to raloxifene 2005 · All participants: daily calcium and cholecalciferol supplementation · Postmenopausal women participating in the Multiple Outcomes of Raloxifene Evaluation trial | 500 mg | — | 213 days | 7,522 |
| Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective 2006 · placebo group with daily supplements · Postmenopausal women aged 42–86 with osteoporosis; age-subgroup analysis included women younger than 75 and women 75 and older | 1 g | — | 578 days | 544 |
| Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective 2006 · teriparatide group with daily supplements · Postmenopausal women aged 42–86 with osteoporosis; age-subgroup analysis included women younger than 75 and women 75 and older | 1 g | — | 578 days | 541 |
| Efficacy of denosumab co-administered with vitamin D and Ca by baseline vitamin D status 2020 · placebo-treated subjects · People with primary osteoporosis; baseline vitamin D status included deficient, insufficient, and sufficient groups; age and sex not stated | 600 mg | 400 IU | 2 years | 481 |
| Efficacy of denosumab co-administered with vitamin D and Ca by baseline vitamin D status 2020 · denosumab-treated subjects · People with primary osteoporosis; baseline vitamin D status included deficient, insufficient, and sufficient groups; age and sex not stated | 600 mg | 400 IU | 2 years | 475 |
| Calcium/vitamin D supplementation, serum 25-hydroxyvitamin D concentrations, and cholesterol profiles in the Women's Health Initiative calcium/vitamin D randomized trial 2014 · CaD · Postmenopausal women aged 50–79 years from the general community | 1 g | 400 IU | — | 291 |
| Effect of calcium and vitamin D supplementation on bone mineral density in women aged 65-71 years: a 3-year randomized population-based trial (OSTPRE-FPS) 2010 · supplementation group · Ambulatory postmenopausal women aged 66 to 71 years | 1 g | 800 IU | 3 years | 287 |
| Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density 2007 · alendronate 10 mg/elemental calcium 1000 mg · Healthy postmenopausal women with low bone mineral density and dietary calcium intake ≥800 mg/day | 1 g | 400 IU | 2 years | 280 |
| Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis 2012 · 1 mg daily minodronate group · Men and postmenopausal women aged 51–89 with involutional osteoporosis | 610 mg | 400 IU | 1 year | 234 |
| Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis 2012 · 30 mg monthly minodronate group · Men and postmenopausal women aged 51–89 with involutional osteoporosis | 610 mg | 400 IU | 1 year | 229 |
| Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis 2012 · 50 mg monthly minodronate group · Men and postmenopausal women aged 51–89 with involutional osteoporosis | 610 mg | 400 IU | 1 year | 229 |
| Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study 2012 · open-label extension · Men with osteoporosis; age range not reported | 1 g | — | 2 years | 218 |
| The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease 2012 · calcium-vitamin D3 fixed combination group (Ca-D3) · Elderly institutionalized women, mean age 85 years, with moderate chronic kidney disease and severe vitamin D deficiency | 1.2 g | 800 IU | 2 years | 206 |
| The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease 2012 · separate calcium and vitamin D3 supplements group (Ca + D3) · Elderly institutionalized women, mean age 85 years, with moderate chronic kidney disease and severe vitamin D deficiency | 1.2 g | 800 IU | 2 years | 189 |
| Renal Phosphate Reabsorption is Correlated with the Increase in Lumbar Bone Mineral Density in Patients Receiving Once-Weekly Teriparatide 2016 · TPTD group · Postmenopausal women and men with osteoporosis; age range not stated | 610 mg | 400 IU | 72 weeks | 153 |
| No significant effect on bone mineral density by high doses of vitamin D3 given to overweight subjects for one year 2010 · DD group · Men and women aged 21–70 with BMI 28.0–47.0 kg/m² who were overweight or obese | 500 mg | — | 1 year | 147 |
| Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density 2007 · alendronate-placebo/calcium 1000 mg · Healthy postmenopausal women with low bone mineral density and dietary calcium intake ≥800 mg/day | 1 g | 400 IU | 2 years | 140 |
| Renal Phosphate Reabsorption is Correlated with the Increase in Lumbar Bone Mineral Density in Patients Receiving Once-Weekly Teriparatide 2016 · Placebo group · Postmenopausal women and men with osteoporosis; age range not stated | 610 mg | 400 IU | 72 weeks | 137 |
| No significant effect on bone mineral density by high doses of vitamin D3 given to overweight subjects for one year 2010 · DP group · Men and women aged 21–70 with BMI 28.0–47.0 kg/m² who were overweight or obese | 500 mg | — | 1 year | 132 |
| Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy 2006 · Placebo subcutaneous plus HRT · Postmenopausal women with low bone mass or osteoporosis | 1 g | — | 60 weeks | 125 |
| Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy 2006 · Teriparatide 40 microg/day (SC) plus HRT (TPTD40 + HRT) · Postmenopausal women with low bone mass or osteoporosis | 1 g | — | 60 weeks | 122 |
| Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17 2006 · letrozole · Postmenopausal women with primary breast cancer who completed at least 5 years of adjuvant tamoxifen and had baseline BMD T score of at least 2.0 in either the hip or L2–4 spine | 500 mg | — | 2 years | 122 |
| Menatetrenone versus alfacalcidol in the treatment of Chinese postmenopausal women with osteoporosis: a multicenter, randomized, double-blinded, double-dummy, positive drug-controlled clinical trial 2014 · Group A (alfacalcidol) · Women aged 45–75 years, postmenopausal for at least 5 years, with osteoporosis | 500 mg | 0.5 mcg | 1 year | 118 |
| Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis 2015 · ALN + VitD group · Japanese men and women aged 60–90 with primary osteoporosis or osteopenia and at least one vertebral fracture | 610 mg | 400 IU | 48 weeks | 109 |
| Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial 2018 · Placebo group · Youth aged 16–24 years with HIV, RNA load <200 copies/mL, taking TDF-containing combination antiretroviral therapy for at least 180 days | 162 mg | — | 48 weeks | 105 |
| Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17 2006 · placebo · Postmenopausal women with primary breast cancer who completed at least 5 years of adjuvant tamoxifen and had baseline BMD T score of at least 2.0 in either the hip or L2–4 spine | 500 mg | — | 2 years | 104 |
| Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis 2004 · group A · Adults with established glucocorticoid-induced osteoporosis receiving long-term glucocorticoid therapy, with or without vertebral fractures; underlying conditions included chronic obstructive pulmonary disease, rheumatoid arthritis, and polymyalgia rheumatica | 500 mg | 1 mcg | 3 years | 103 |
| A randomized controlled trial of calcium supplementation to increase bone mineral density in children with juvenile rheumatoid arthritis 2006 · Calcium group · Children and adolescents aged 6–18 years with juvenile rheumatoid arthritis who had not taken corticosteroids for at least 3 months | 1 g | 400 IU | 2 years | 103 |
| [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis] 2004 · RLX group · Chinese postmenopausal women with osteoporosis | 500 mg | — | 1 year | 102 |
| [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis] 2004 · placebo group · Chinese postmenopausal women with osteoporosis | 500 mg | — | 1 year | 102 |
| Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis 2004 · group B · Adults with established glucocorticoid-induced osteoporosis receiving long-term glucocorticoid therapy, with or without vertebral fractures; underlying conditions included chronic obstructive pulmonary disease, rheumatoid arthritis, and polymyalgia rheumatica | 500 mg | 1,000 IU | 3 years | 101 |
| Limited reduction of bone mineral density in patients with early rheumatoid arthritis receiving aggressive treatment: 10 year results of the NEO-RACo study 2025 · All patients · Patients aged 18–60 years with early active rheumatoid arthritis and no earlier use of disease-modifying anti-rheumatic drugs | 1 g | 800 IU | — | 99 |
| Formula Milk Supplementation and Bone Acquisition in 4-6 Years Chinese Children: A 12-Month Cluster-Randomized Controlled Trial 2023 · formula milk group · Healthy Chinese children aged 4–6 years in rural Northwest China who were willing to drink milk but consumed little for economic reasons | 720 mg | 4.5 mcg | 1 year | 96 |
| Prediction of bone mass density variation by bone remodeling markers in postmenopausal women with vitamin D insufficiency treated with calcium and vitamin D supplementation 2003 · supplementation · Ambulatory elderly women, mean age 75 years, with vitamin D insufficiency | 1 g | 800 IU | 1 year | 95 |
| Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial 2015 · VitD/Cal group · HIV-infected adults initiating their first ART regimen with EFV/FTC/TDF | 1 g | 4,000 IU | 48 weeks | 81 |
| Efficacy of strontium ranelate on bone mineral density in men with osteoporosis 2010 · Strontium ranelate group · Men with primary osteoporosis | 1.2 g | 800 IU | 1 year | 76 |
| Efficacy of strontium ranelate on bone mineral density in men with osteoporosis 2010 · Alendronate group · Men with primary osteoporosis | 1.2 g | 800 IU | 1 year | 76 |
| Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women 2001 · vitamin D(3) and calcium group · Elderly women with 25-hydroxycholecalciferol below 50 nmol/L; mean age 74 years | 1.2 g | 800 IU | 8 weeks | 74 |
| Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis 2006 · vitamin D plus calcium group · Postmenopausal Caucasian patients with osteoporosis and normal vitamin D serum levels | 1 g | 880 IU | 547 days | 72 |
| Estimating the causal effect of milk powder supplementation on bone mineral density: a randomized controlled trial with both non-compliance and loss to follow-up 2015 · milk powder supplementation group · Healthy postmenopausal women | 900 mg | 800 IU | 2 years | 69 |
| The benefits of a high-intensity aquatic exercise program (HydrOS) for bone metabolism and bone mass of postmenopausal women 2014 · Aquatic Exercise Group (AEG) · Postmenopausal women, mean age 58.8 ± 6.4 years | 500 mg | 1,000 IU | 24 weeks | 64 |
| Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D 2011 · group B · Patients with Crohn's disease and reduced BMD (T-score < -1) | 800 mg | 1,000 IU | 1278 days | 62 |
| Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium 2003 · simple vitamin D (ergocalciferol) plus calcium carbonate · Females and males commencing or already taking glucocorticoids | 600 mg | 4,286 IU | 2 years | 61 |
| Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study 2012 · 500 mg calcium with 400 international unis (iu) vitamin D daily · Adults with β-thalassaemia and osteoporosis (BMD Z scores ≤-2·0) | 500 mg | 400 IU | 1 year | 59 |
| Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study 2012 · 500 mg calcium with 400 iu vitamin D daily plus neridronate 100 mg intravenously every 90 d · Adults with β-thalassaemia and osteoporosis (BMD Z scores ≤-2·0) | 500 mg | 400 IU | 1 year | 59 |
| A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study 2006 · calcitonin group · Postmenopausal Asian women with osteoporosis | 500 mg | — | 26 weeks | 57 |
| Effectiveness of bazedoxifene in preventing glucocorticoid-induced bone loss in rheumatoid arthritis patients 2021 · bazedoxifene group · Postmenopausal women aged 45 years or older with rheumatoid arthritis and osteopenia, receiving low-dose glucocorticoids | 1.2 g | 800 IU | 56 weeks | 57 |
| Effectiveness of bazedoxifene in preventing glucocorticoid-induced bone loss in rheumatoid arthritis patients 2021 · control group · Postmenopausal women aged 45 years or older with rheumatoid arthritis and osteopenia, receiving low-dose glucocorticoids | 1.2 g | 800 IU | 56 weeks | 57 |
| Effects of milk powder intervention on bone mineral density and indicators related to bone metabolism in Chinese adolescents 2019 · Ca6D group · Healthy Chinese adolescents aged 11.9–15.2 years | 600 mg | 400 IU | 548 days | 56 |
| Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation 2006 · Control group · Patients with orthotopic liver transplantation | 1 g | 0.5 mcg | 2 years | 54 |
| Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D 2011 · group C · Patients with Crohn's disease and reduced BMD (T-score < -1) | 800 mg | 1,000 IU | 1278 days | 54 |
| Effects of milk powder intervention on bone mineral density and indicators related to bone metabolism in Chinese adolescents 2019 · Ca9D group · Healthy Chinese adolescents aged 11.9–15.2 years | 900 mg | 400 IU | 548 days | 54 |
| Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients 2008 · experiment I group · Patients on maintenance dialysis with chronic renal failure, at risk of osteoporosis; age and sex not specified | 4.5 g | 0.25 mcg | 1 year | 50 |
| Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients 2008 · experiment II group · Patients on maintenance dialysis with chronic renal failure, at risk of osteoporosis; age and sex not specified | 4.5 g | 0.25 mcg | 1 year | 50 |
| Effects of vitamin D and calcium supplementation on bone mineral density among Thai youth using daily HIV pre-exposure prophylaxis 2020 · Arm A (TDF/FTC + Oskept) · Young men who have sex with men and young transgender women aged 15–24 years initiating PrEP | 1.2 g | — | 26 weeks | 50 |
| Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride 2002 · calcium-vitamin D-placebo group · Adults with inflammatory bowel disease and osteoporosis (lumbar spine T score below -2 standard deviations), median age 35 years; normal serum 25OH vitamin D | 1 g | 800 IU | 1 year | 49 |
| Effects of milk powder intervention on bone mineral density and indicators related to bone metabolism in Chinese adolescents 2019 · Ca3D group · Healthy Chinese adolescents aged 11.9–15.2 years | 300 mg | 400 IU | 548 days | 49 |
| A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study 2006 · teriparatide group · Postmenopausal Asian women with osteoporosis | 500 mg | — | 26 weeks | 47 |
| Effect of pamidronate on bone loss after kidney transplantation: a randomized trial 2009 · control group · Kidney transplant recipients with parathyroid hormone level at least 150 pg/mL | 500 mg | — | 2 years | 47 |
| Effect of pamidronate on bone loss after kidney transplantation: a randomized trial 2009 · treatment group · Kidney transplant recipients with parathyroid hormone level at least 150 pg/mL | 500 mg | — | 2 years | 46 |
| Effects of monthly intramuscular neridronate in rheumatic patients in chronic treatment with low-dose glucocorticoids 2009 · Group B · Patients with rheumatic diseases, osteopenia or osteoporosis, and gastric or esophageal conditions contraindicating oral bisphosphonates; receiving chronic low-dose glucocorticoids | 1 g | — | 1 year | 46 |
| Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride 2002 · calcium-vitamin D-fluoride group · Adults with inflammatory bowel disease and osteoporosis (lumbar spine T score below -2 standard deviations), median age 35 years; normal serum 25OH vitamin D | 1 g | 800 IU | 1 year | 45 |
| Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation 2004 · calcitriol therapy (CT) · renal transplant recipients; age and sex not specified | 500 mg | 0.25 mcg | 90 days | 45 |
| Effect of early risedronate treatment on bone mineral density and bone turnover markers after liver transplantation: a prospective single-center study 2011 · Risedronate plus calcium and vitamin D3 · Patients with osteopenia or osteoporosis within the first month after liver transplantation | 1 g | 800 IU | 1 year | 45 |
| Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation 2006 · ALN 70 mg weekly · Patients with orthotopic liver transplantation | 1 g | 0.5 mcg | 2 years | 44 |
| Effect of early risedronate treatment on bone mineral density and bone turnover markers after liver transplantation: a prospective single-center study 2011 · Calcium and vitamin D3 · Patients with osteopenia or osteoporosis within the first month after liver transplantation | 1 g | 800 IU | 1 year | 44 |
| The benefits of a high-intensity aquatic exercise program (HydrOS) for bone metabolism and bone mass of postmenopausal women 2014 · Control Group (CG) · Postmenopausal women, mean age 58.8 ± 6.4 years | 500 mg | 1,000 IU | 24 weeks | 44 |
| A Randomized Placebo-Controlled Trial of Low- Versus Moderate-Dose Vitamin D3 Supplementation on Bone Mineral Density in Postmenopausal Women With HIV 2019 · Low VitD group · Postmenopausal African American or Hispanic women aged 40–70 with HIV, serum 25-OHD 10–32 ng/mL, on stable antiretroviral therapy | 1 g | 1,000 IU | 1 year | 43 |
| A Randomized Placebo-Controlled Trial of Low- Versus Moderate-Dose Vitamin D3 Supplementation on Bone Mineral Density in Postmenopausal Women With HIV 2019 · Moderate VitD group · Postmenopausal African American or Hispanic women aged 40–70 with HIV, serum 25-OHD 10–32 ng/mL, on stable antiretroviral therapy | 1 g | 3,000 IU | 1 year | 42 |
| The effects of calcitriol therapy on serum interleukin-1, interleukin-6 and tumour necrosis factor-alpha concentrations in post-menopausal patients with osteoporosis 2004 · Calcitriol and calcium group · Post-menopausal women with osteoporosis | 1 g | 0.5 mcg | 26 weeks | 40 |
| The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures--an open label study 2005 · Treatment group · Men with idiopathic osteoporosis, mean age 59 ± 6 years, without vertebral fractures | 1 g | 400 IU | 548 days | 40 |
| Vitamin K supplement along with vitamin D and calcium reduced serum concentration of undercarboxylated osteocalcin while increasing bone mineral density in Korean postmenopausal women over sixty-years-old 2011 · treatment group (vitamin K) · Postmenopausal Korean women over 60 years old | 630 mg | 400 IU | 26 weeks | 40 |
| Effects of 1 alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis 1994 · 1 alpha(OH)D3 treatment · Postmenopausal Japanese women with osteoporosis; mean age 71.9 years | 300 mg | — | 1 year | 40 |
| Intravenous intermittent neridronate in the treatment of postmenopausal osteoporosis 2003 · Neridronate group · Postmenopausal women with spine bone mineral density at least 2.5 SD below peak | 500 mg | — | 3 years | 39 |
| Intravenous intermittent neridronate in the treatment of postmenopausal osteoporosis 2003 · Control group · Postmenopausal women with spine bone mineral density at least 2.5 SD below peak | 500 mg | — | 3 years | 39 |
| Skeletal site-dependent response of bone mineral density and quantitative ultrasound parameters following a 12-month dietary intervention using dairy products fortified with calcium and vitamin D: the Postmenopausal Health Study 2006 · dairy group (DG) · Postmenopausal women aged 55–65 years | 1.2 g | 7.5 mcg | 1 year | 39 |
| Changes in biochemical indexes of bone metabolism and bone mineral density after a 12-mo dietary intervention program: the Postmenopausal Health Study 2007 · dairy intervention group · postmenopausal women | 1.2 g | 7.5 mcg | 1 year | 39 |
| Vitamin K supplement along with vitamin D and calcium reduced serum concentration of undercarboxylated osteocalcin while increasing bone mineral density in Korean postmenopausal women over sixty-years-old 2011 · control group · Postmenopausal Korean women over 60 years old | 630 mg | 400 IU | 26 weeks | 38 |
| Cardiometabolic Indices after Weight Loss with Calcium or Dairy Foods: Secondary Analyses from a Randomized Trial with Overweight/Obese Postmenopausal Women 2022 · Supplement group (S) · Overweight/obese, generally healthy postmenopausal women with dietary calcium intake of 800 mg/day or less | 315 mg | 200 IU | 26 weeks | 37 |
| Effects of dietary improvement on bone metabolism in elderly underweight women with osteoporosis: a randomised controlled trial 2003 · Group 2 · Women aged 70 years or older with BMI ≤21 kg/m² and hip osteoporosis | 1 g | 800 IU | 1 year | 36 |
| Effects of dietary improvement on bone metabolism in elderly underweight women with osteoporosis: a randomised controlled trial 2003 · Group 1 · Women aged 70 years or older with BMI ≤21 kg/m² and hip osteoporosis | 1 g | 800 IU | 1 year | 35 |
| The effects of a 30-month dietary intervention on bone mineral density: the Postmenopausal Health Study 2010 · dietary group (DG) · Postmenopausal women aged 55–65 years | 1.2 g | — | 913 days | 35 |
| Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial 2011 · Vitamin D3 · Adults aged 18–50 with clinically definite multiple sclerosis, fully ambulatory (EDSS ≤4.5) | 500 mg | 2,857 IU | 96 weeks | 35 |
| Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women 2002 · placebo · Postmenopausal African-American women aged 45–88 with osteoporosis | 500 mg | 500 IU | 2 years | 33 |
| Overweight postmenopausal women lose bone with moderate weight reduction and 1 g/day calcium intake 2005 · WL Hi-Ca · Overweight postmenopausal women aged 50–75 undergoing weight loss | 1.2 g | 400 IU | 180 days | 33 |
| The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis 2006 · raloxifene group · Postmenopausal women with diagnosed osteoporosis | 500 mg | 800 IU | 2 years | 33 |
| The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis 2006 · placebo group · Postmenopausal women with diagnosed osteoporosis | 500 mg | 800 IU | 2 years | 33 |
| The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis 2006 · continuation of open-label alendronate group · Postmenopausal women with diagnosed osteoporosis | 500 mg | 800 IU | 2 years | 33 |
| Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women 2002 · alendronate group · Postmenopausal African-American women aged 45–88 with osteoporosis | 500 mg | 500 IU | 2 years | 32 |
| Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D 2011 · group A · Patients with Crohn's disease and reduced BMD (T-score < -1) | 800 mg | 1,000 IU | 1278 days | 32 |
| The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures--an open label study 2005 · Control group · Men with idiopathic osteoporosis, mean age 59 ± 6 years, without vertebral fractures | 1 g | 400 IU | 548 days | 31 |
| Daily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects: a pilot study 2006 · PTH250 · Adults aged 52–84 years with osteoporosis | 300 mg | 200 IU | 90 days | 31 |
| Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial 2004 · treatment group · Healthy adults; age and sex not specified | 500 mg | 500 IU | 213 days | 30 |
| [Prevention of glucocorticoid-induced osteoporosis in patients with primary glomerulonephritis] 2005 · Group A · Adults aged 18–50 with primary glomerulonephritis receiving glucocorticoid treatment | 2.25 g | 1 mcg | 1 year | 30 |
| [Prevention of glucocorticoid-induced osteoporosis in patients with primary glomerulonephritis] 2005 · Group B · Adults aged 18–50 with primary glomerulonephritis receiving glucocorticoid treatment | 2.25 g | 0.5 mcg | 1 year | 30 |
| Daily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects: a pilot study 2006 · PTH500 · Adults aged 52–84 years with osteoporosis | 300 mg | 200 IU | 90 days | 30 |
| Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial) 2007 · group A · Adults with established postmenopausal or male osteoporosis | 500 mg | 1 mcg | 2 years | 30 |
| Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial) 2007 · group B · Adults with established postmenopausal or male osteoporosis | 1 g | 1,000 IU | 2 years | 30 |
| Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial) 2007 · group C · Adults with established postmenopausal or male osteoporosis | 500 mg | 1 mcg | 2 years | 30 |
| Clodronic acid in the treatment of postmenopausal osteoporosis 2007 · clodronic acid group · Postmenopausal women aged 48–73 years with osteoporosis | 500 mg | 400 IU | 3 years | 30 |
| Effect of calcium plus vitamin D supplementation during pregnancy in Brazilian adolescent mothers: a randomized, placebo-controlled trial 2013 · calcium plus vitamin D · Pregnant adolescents aged 14–19 years with low-calcium diets | 600 mg | 200 IU | — | 30 |
| Calcium plus vitamin D supplementation during pregnancy interacts with polymorphisms in the promoter region of the VDR gene to affect postpartum bone mass of Brazilian adolescent mothers: A randomized controlled trial 2016 · calcium plus cholecalciferol · Pregnant adolescents aged 14–19 years | 600 mg | 200 IU | — | 30 |
| Reduction in Bone Loss from 5 to 20 Weeks Postpartum in Adolescents Supplemented with Calcium Plus Vitamin D during Pregnancy Is Not Sustained at 1 Year Postpartum: Follow-up Study of a Randomized Controlled Trial 2021 · supplemented group · Pregnant adolescents aged 14–19 years with habitually low calcium intake | 600 mg | 200 IU | — | 30 |
| Amelioration of hemiplegia-associated osteopenia more than 4 years after stroke by 1 alpha-hydroxyvitamin D3 and calcium supplementation 1997 · treatment group · Patients with hemiplegia after stroke; mean duration of illness 4.8 years; age and sex not reported | 300 mg | 1 mcg | 26 weeks | 30 |
| Daily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects: a pilot study 2006 · PTH1000 · Adults aged 52–84 years with osteoporosis | 300 mg | 200 IU | 90 days | 29 |
| Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial) 2008 · Control group · Adults aged 18 years or older with cystic fibrosis and low bone mass | 500 mg | 800 IU | 1 year | 29 |
| Effectiveness of resistance training or jumping-exercise to increase bone mineral density in men with low bone mass: A 12-month randomized, clinical trial 2015 · Resistance training (RT) · Men aged 25–60 years with low lumbar-spine or hip bone mass; apparently healthy and physically active | 1 g | 10 mcg | 1 year | 29 |
| Effectiveness of resistance training or jumping-exercise to increase bone mineral density in men with low bone mass: A 12-month randomized, clinical trial 2015 · Jump training (JUMP) · Men aged 25–60 years with low lumbar-spine or hip bone mass; apparently healthy and physically active | 1 g | 10 mcg | 1 year | 29 |
| [The efficacy of alendronate in the prevention and treatment of postmenopausal osteoporosis] 2002 · alendronate group · Postmenopausal women with osteopenia or osteoporosis | 600 mg | — | 26 weeks | 28 |
| [The efficacy of alendronate in the prevention and treatment of postmenopausal osteoporosis] 2002 · placebo group · Postmenopausal women with osteopenia or osteoporosis | 600 mg | — | 26 weeks | 28 |
| Additive effects of nutritional supplementation, together with bisphosphonates, on bone mineral density after hip fracture: a 12-month randomized controlled study 2014 · B · Adults aged 61–96 years with a recent hip fracture | 1 g | 800 IU | 1 year | 28 |
| Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial) 2008 · Alendronate group · Adults aged 18 years or older with cystic fibrosis and low bone mass | 500 mg | 800 IU | 1 year | 27 |
| Bone mass decreases in morbidly obese women after long limb-biliopancreatic diversion and marked weight loss without secondary hyperparathyroidism. A physiological adaptation to weight loss? 2009 · Group A · Healthy, morbidly obese, premenopausal women undergoing long limb-biliopancreatic diversion | 100 mg | 200 IU | 1 year | 26 |
| Bone mass decreases in morbidly obese women after long limb-biliopancreatic diversion and marked weight loss without secondary hyperparathyroidism. A physiological adaptation to weight loss? 2009 · Group B · Healthy, morbidly obese, premenopausal women undergoing long limb-biliopancreatic diversion | 2.1 g | 200 IU | 1 year | 26 |
| Possible site-specific effect of an intervention combining nutrition and lifestyle counselling with consumption of fortified dairy products on bone mass: the Postmenopausal Health Study II 2011 · CaD group · Postmenopausal women | 800 mg | 10 mcg | 1 year | 26 |
| Possible site-specific effect of an intervention combining nutrition and lifestyle counselling with consumption of fortified dairy products on bone mass: the Postmenopausal Health Study II 2011 · CaDK1 group · Postmenopausal women | 800 mg | 10 mcg | 1 year | 26 |
| Additive effects of nutritional supplementation, together with bisphosphonates, on bone mineral density after hip fracture: a 12-month randomized controlled study 2014 · BN · Adults aged 61–96 years with a recent hip fracture | 1 g | 800 IU | 26 weeks | 26 |
| Additive effects of nutritional supplementation, together with bisphosphonates, on bone mineral density after hip fracture: a 12-month randomized controlled study 2014 · C · Adults aged 61–96 years with a recent hip fracture | 1 g | 800 IU | 1 year | 25 |
| Effects of a Multispecies Probiotic Supplement on Bone Health in Osteopenic Postmenopausal Women: A Randomized, Double-blind, Controlled Trial 2017 · multispecies probiotic supplement (GeriLact) · Postmenopausal women aged 50–72 years with osteopenia | 500 mg | 200 IU | 26 weeks | 25 |
| Possible site-specific effect of an intervention combining nutrition and lifestyle counselling with consumption of fortified dairy products on bone mass: the Postmenopausal Health Study II 2011 · CaDK2 group · Postmenopausal women | 800 mg | 10 mcg | 1 year | 24 |
| Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120) 2012 · placebo group · HIV-1-infected adults with low bone mineral density and no other known risk factors for low BMD; antiretroviral-treated | 500 mg | — | 96 weeks | 24 |
| Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women 1998 · E + C group · Postmenopausal women with at least one non-traumatic vertebral fracture or z score < -1.5 | 500 mg | 0.5 mcg | 1 year | 24 |
| Effects of monthly intramuscular neridronate in rheumatic patients in chronic treatment with low-dose glucocorticoids 2009 · Group A · Patients with rheumatic diseases, osteopenia or osteoporosis, and gastric or esophageal conditions contraindicating oral bisphosphonates; receiving chronic low-dose glucocorticoids | 1 g | — | 1 year | 23 |
| Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing's syndrome 2009 · group 1 · Premenopausal women aged 43.1 ± 7.7 years with subclinical Cushing's syndrome due to adrenal incidentaloma and osteoporosis or osteopenia | 500 mg | 800 mg | 1 year | 23 |
| Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing's syndrome 2009 · group 2 · Premenopausal women aged 43.1 ± 7.7 years with subclinical Cushing's syndrome due to adrenal incidentaloma and osteoporosis or osteopenia | 500 mg | 800 mg | 1 year | 23 |
| Treatment with raloxifene for 2 years increases vertebral bone mineral density as measured by volumetric quantitative computed tomography 2004 · RLX 120 mg/day · Postmenopausal women with osteoporosis | 500 mg | — | 2 years | 20 |
| Effects of neridronate treatment in elderly women with osteoporosis 2005 · Neridronate plus calcium and vitamin D · Postmenopausal women aged 65–80 with osteoporosis | 500 mg | — | 1 year | 20 |
| Effects of neridronate treatment in elderly women with osteoporosis 2005 · Calcium plus vitamin D supplements alone · Postmenopausal women aged 65–80 with osteoporosis | 500 mg | — | 1 year | 20 |
| Calcium and vitamin D supplementation through fortified dairy products counterbalances seasonal variations of bone metabolism indices: the Postmenopausal Health Study 2011 · dietary group (DG) · Postmenopausal women aged 55–65 with osteopenia | 1.2 g | — | 913 days | 20 |
| Efficacy and tolerability of calcium, vitamin D and a plant-based omega-3 oil for osteopenia: a pilot RCT 2012 · Algal oil containing DHA · Individuals with osteopenia | 1.2 g | 1,000 IU | 1 year | 20 |
| Efficacy and tolerability of calcium, vitamin D and a plant-based omega-3 oil for osteopenia: a pilot RCT 2012 · Placebo group · Individuals with osteopenia | 1.2 g | 1,000 IU | 1 year | 20 |
| Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120) 2012 · alendronate group · HIV-1-infected adults with low bone mineral density and no other known risk factors for low BMD; antiretroviral-treated | 500 mg | — | 96 weeks | 20 |
| A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis 1998 · Combined therapy group · Postmenopausal women with established osteoporosis; mean age 64.9 years | 1 g | — | 4 years | 19 |
| Increase of bone mineral density with sodium fluoride in patients with Crohn's disease 2000 · calcium/vitamin D/fluoride group · Patients with chronic active Crohn's disease and osteoporosis; all had received systemic high-dose steroid therapy during the previous year | 1 g | 1,000 IU | 1 year | 18 |
| Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation 2000 · Control subjects · Patients with cystic fibrosis after lung transplantation | 1 g | 800 IU | 2 years | 18 |
| A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis 1998 · Control group · Postmenopausal women with established osteoporosis; mean age 64.9 years | 1 g | — | 4 years | 18 |
| A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis 1998 · HRT group · Postmenopausal women with established osteoporosis; mean age 64.9 years | 1 g | — | 4 years | 18 |
| Treatment with raloxifene for 2 years increases vertebral bone mineral density as measured by volumetric quantitative computed tomography 2004 · RLX 60 mg/day · Postmenopausal women with osteoporosis | 500 mg | — | 2 years | 17 |
| A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis 1998 · Etidronate group · Postmenopausal women with established osteoporosis; mean age 64.9 years | 1 g | — | 4 years | 17 |
| Effect of 1,25-dihydroxyvitamin D3 and calcium carbonate on bone loss associated with long-term renal transplantation 2000 · treatment group · Long-term renal transplant recipients with serum creatinine levels less than 2.0 mg/dL | 500 mg | 0.25 mcg | 1 year | 16 |
| Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation 2000 · Pamidronate treatment group · Patients with cystic fibrosis after lung transplantation | 1 g | 800 IU | 2 years | 16 |
| Efficacy of strontium ranelate in combination with a D-hormone analog for the treatment of postmenopausal osteoporosis 2014 · SrRan monotherapy · Postmenopausal women aged 54–73 with osteoporosis | 1 g | 800 IU | 26 weeks | 16 |
| Efficacy of strontium ranelate in combination with a D-hormone analog for the treatment of postmenopausal osteoporosis 2014 · SrRan + AD3 · Postmenopausal women aged 54–73 with osteoporosis | 1 g | 800 IU | 26 weeks | 16 |
| Efficacy of strontium ranelate in combination with a D-hormone analog for the treatment of postmenopausal osteoporosis 2014 · Control · Postmenopausal women aged 54–73 with osteoporosis | 1 g | 800 IU | 26 weeks | 16 |
| Increase of bone mineral density with sodium fluoride in patients with Crohn's disease 2000 · calcium/vitamin D only group · Patients with chronic active Crohn's disease and osteoporosis; all had received systemic high-dose steroid therapy during the previous year | 1 g | 1,000 IU | 1 year | 15 |
| Randomised double blind placebo controlled trial investigating the effect of calcium and vitamin D supplementation on bone mineral density and bone metabolism in adult patients with cystic fibrosis 2004 · calcium and vitamin D treatment group · Adults with cystic fibrosis and a BMD Z score of -1 or less in the lumbar spine, proximal femur or distal forearm | 1 g | 1,700 IU | 1 year | 15 |
| Effect of zoledronic acid on bone mineral density in patients of celiac disease: a prospective, randomized, pilot study 2013 · Group B (drug arm) · Adults aged 18 years or older with newly diagnosed celiac disease and low bone mineral density | 1 g | — | 1 year | 15 |
| Therapy of steroid-induced bone loss in adult asthmatics with calcium, vitamin D, and a diphosphonate 1994 · treated group · Adults with asthma undergoing long-term systemic corticosteroid treatment | 1 g | 1,000 IU | 26 weeks | 14 |
| Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers 2000 · Vehicle group · Men aged 30–68 with idiopathic osteoporosis | 1.5 g | 400 IU | 548 days | 13 |
| Effect of zoledronic acid on bone mineral density in patients of celiac disease: a prospective, randomized, pilot study 2013 · Group A (control arm) · Adults aged 18 years or older with newly diagnosed celiac disease and low bone mineral density | 1 g | — | 1 year | 13 |
| Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers 2000 · PTH-(1-34) group · Men aged 30–68 with idiopathic osteoporosis | 1.5 g | 400 IU | 548 days | 10 |
| Vitamin D and Calcium Supplement Attenuate Bone Loss among HIVInfected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/ Efavirenz: An Open-Label, Randomized Controlled Trial 2020 · study group · Adults aged 18–50 with HIV infection, ART-naïve at enrollment and starting TDF/FTC/EFV; mostly men | 1.25 g | 2,857 IU | 24 weeks | 9 |
| Effect of disodium monofluorophosphate, calcium and vitamin D supplementation on bone mineral density in patients chronically treated with glucocorticosteroids: a prospective, randomized, double-blind study 1996 · Group 1 · Adults with renal grafts or skin, bronchopulmonary, or Crohn's disease, chronically treated with glucocorticosteroids | 1 g | — | 1 year | 8 |
| Effect of treatment on bone mass, mineral metabolism, and body composition in untreated celiac disease patients 1997 · diet plus calcium and vitamin D · Adults with newly diagnosed, untreated celiac disease; 11 of the 14 patients had osteopenia at diagnosis | 1 g | 4,571 IU | 1 year | 7 |
| Prevention of bone loss after withdrawal of tamoxifen 2008 · alendronate group · Postmenopausal women with a history of breast cancer who had stopped tamoxifen; mean age 58 years | 1.2 g | — | 1 year | 6 |
| Effect of low-dose calcitriol and calcium therapy on bone histomorphometry and urinary calcium excretion in osteopenic women 1990 · Ergocalciferol-treated group · Women over 60 years of age with osteopenia | 1 g | — | 1 year | 6 |
| Prevention of bone loss after withdrawal of tamoxifen 2008 · placebo group · Postmenopausal women with a history of breast cancer who had stopped tamoxifen; mean age 58 years | 1.2 g | — | 1 year | 5 |
| Effect of low-dose calcitriol and calcium therapy on bone histomorphometry and urinary calcium excretion in osteopenic women 1990 · Calcitriol-treated group · Women over 60 years of age with osteopenia | 1 g | 0.5 mcg | 1 year | 4 |
| Prevention of osteoporosis after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol 1999 · calcitriol group · Adults after cardiac transplantation; mean age 51 years, 111 male and 21 female across the study; sex-specific arm ages not reported | 1 g | — | 3 years | — |
| Prevention of postmenopausal bone loss by low and conventional doses of calcitriol or conjugated equine estrogen 2000 · calcium and calcitriol at 0.25 microg daily · Thai postmenopausal women no more than 6 years postmenopausal | 750 mg | 0.25 mcg | 2 years | — |
| Prevention of postmenopausal bone loss by low and conventional doses of calcitriol or conjugated equine estrogen 2000 · calcium and calcitriol at 0.5 microg daily · Thai postmenopausal women no more than 6 years postmenopausal | 750 mg | 0.5 mcg | 2 years | — |
| Effect of calcitriol on bone mineral density in premenopausal Chinese women taking chronic steroid therapy. A randomized, double blind, placebo controlled study 2000 · Group 1 · Premenopausal women aged 31.1 ± 6 years with systemic lupus erythematosus taking chronic steroid therapy | 1.2 g | 0.5 mcg | 2 years | — |
| Effect of calcitriol on bone loss after cardiac or lung transplantation 2000 · Calcitriol for 12 months followed by calcium for 12 months · Patients undergoing cardiac or single lung transplantation; age and sex not specified | 600 mg | — | 2 years | — |
| Effect of calcitriol on bone loss after cardiac or lung transplantation 2000 · Calcitriol for 24 months · Patients undergoing cardiac or single lung transplantation; age and sex not specified | 600 mg | — | 2 years | — |
| Effect of intermittent cyclical treatment with etidronate disodium (HEBP) and calcium plus alphacalcidol in postmenopausal osteoporosis 2001 · HEBP group · Women over 50 years old with postmenopausal osteoporosis, low BMD and lumbo-dorsal pain | 2 g | 0.5 mcg | 2 years | — |
| Effect of intermittent cyclical treatment with etidronate disodium (HEBP) and calcium plus alphacalcidol in postmenopausal osteoporosis 2001 · Ca. D group · Women over 50 years old with postmenopausal osteoporosis, low BMD and lumbo-dorsal pain | 2 g | 0.5 mcg | 2 years | — |
| Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study 2002 · CaD group · Adult renal transplant recipients; 65 men and 46 women, mean age 47 years | 1 g | 0.25 mcg | 26 weeks | — |
| Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate 2003 · group A · Patients with Crohn's disease and pathological bone mineral density findings | 800 mg | 1,000 IU | 821 days | — |
| Vitamin D supplementation and bone mineral density in early postmenopausal women 2003 · 1000 mg Ca/d plus 10 000 U vitamin D(2)/wk · Postmenopausal women at least 1 year after menopause; mean age 56 years | 1 g | — | 2 years | — |
| A randomized trial comparing hormone replacement therapy (HRT) and HRT plus calcitriol in the treatment of postmenopausal osteoporosis with vertebral fractures: benefit of the combination on total body and hip density 2003 · HRT/D group · Postmenopausal women aged 53–79 years with osteoporosis, at least one minimal-trauma vertebral fracture, and low lumbar bone mineral density | 600 mg | 0.5 mcg | 2 years | — |
| Preventing bone loss in renal transplant recipients with vitamin D 2003 · group 1 · adult men who were recent renal transplant recipients | 500 mg | 0.5 mcg | — | — |
| A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease 2003 · calcium and vitamin D alone · Patients with Crohn's disease and low bone mineral density at the lumbar spine and/or hip | 500 mg | 400 IU | 1 year | — |
| A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease 2003 · calcium and vitamin D with intravenous pamidronate · Patients with Crohn's disease and low bone mineral density at the lumbar spine and/or hip | 500 mg | 400 IU | 1 year | — |
| An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis 2004 · Transdermal HRT group · Postmenopausal women with primary biliary cirrhosis | 1 g | 0.25 mcg | 2 years | — |
| An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis 2004 · Control group · Postmenopausal women with primary biliary cirrhosis | 1 g | 0.25 mcg | 2 years | — |
| Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension 2004 · alendronate 10 mg/day group · Women aged 60–86 years with low BMD who had received alendronate in FIT | 500 mg | 250 IU | 3 years | — |
| Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension 2004 · alendronate 5 mg/day group · Women aged 60–86 years with low BMD who had received alendronate in FIT | 500 mg | 250 IU | 3 years | — |
| Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension 2004 · placebo group · Women aged 60–86 years with low BMD who had received alendronate in FIT | 500 mg | 250 IU | 3 years | — |
| The effect of calcium and vitamin D3 supplementation on the healing of the proximal humerus fracture: a randomized placebo-controlled study 2004 · vitamin D3 plus calcium · Women aged 58–88 with a proximal humerus fracture and osteoporosis or osteopenia | 1 g | 800 IU | 12 weeks | — |
| Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease 2005 · Etidronate group · Patients with Crohn's disease and decreased bone mineral density | 500 mg | 400 IU | 2 years | — |
| Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease 2005 · Non-etidronate group · Patients with Crohn's disease and decreased bone mineral density | 500 mg | 400 IU | 2 years | — |
| Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate 2005 · Calcium, vitamin D, and sex hormone replacement group · Adults who received an allogeneic stem cell transplant | 1 g | 800 IU | 1 year | — |
| Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate 2005 · Calcium, vitamin D, sex hormone replacement, and pamidronate group · Adults who received an allogeneic stem cell transplant | 1 g | 800 IU | 1 year | — |
| A prospective randomized study for prevention of postrenal transplantation bone loss 2005 · group I · adult male recent renal transplant recipients | 500 mg | 0.5 mcg | 1 year | — |
| Effects of calcium, dairy product, and vitamin D supplementation on bone mass accrual and body composition in 10-12-y-old girls: a 2-y randomized trial 2005 · calcium (1000 mg) + vitamin D3 (200 IU) · Healthy girls aged 10–12 years at Tanner stage I–II with dietary calcium intake below 900 mg/day | 1 g | 200 IU | 2 years | — |
| Prophylactic calcium and vitamin D treatments in steroid-treated children with nephrotic syndrome 2006 · treatment group · Children with nephrotic syndrome receiving prednisolone; mean age 4.6 years, 27 boys and 13 girls across the study | 1 g | 400 IU | 60 days | — |
| Calcium plus vitamin D supplementation and the risk of fractures 2006 · calcium plus vitamin D group · Healthy postmenopausal women aged 50 to 79 years | 1 g | 400 IU | 7 years | — |
| Calcium- and vitamin D3-fortified milk reduces bone loss at clinically relevant skeletal sites in older men: a 2-year randomized controlled trial 2006 · calcium- and vitamin D3-fortified milk group · Men older than 50 years living in the community; mean age 61.9 years | 1 g | 800 IU | 2 years | — |
| Long-term effects of calcium-vitamin-D3-fortified milk on bone geometry and strength in older men 2006 · milk supplementation group · men aged over 50 years; older subgroup analyses included men over 62 years | 1 g | 800 IU | 2 years | — |
| Supplementation with calcium + vitamin D enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations 2007 · calcium + vitamin D supplement group · Healthy overweight or obese women with daily calcium intake below 800 mg | 1.2 g | 400 IU | 15 weeks | — |
| Two-year randomized controlled trial of vitamin K1 (phylloquinone) and vitamin D3 plus calcium on the bone health of older women 2007 · vitamin D3 plus calcium · Healthy, nonosteoporotic Scottish women aged 60 years or older | 1 g | 10 mcg | 2 years | — |
| Two-year randomized controlled trial of vitamin K1 (phylloquinone) and vitamin D3 plus calcium on the bone health of older women 2007 · combined vitamins K1 and D3 plus calcium · Healthy, nonosteoporotic Scottish women aged 60 years or older | 1 g | 10 mcg | 2 years | — |
| Bone mineral density and bone markers in patients with a recent low-energy fracture: effect of 1 y of treatment with calcium and vitamin D 2007 · calcium and vitamin D intervention group · Patients with a recent low-energy fracture of the hip, forearm, shoulder, or spine; mean age 70 ± 11 years, 84% women | 3 g | 1,400 IU | 1 year | — |
| Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis 2007 · Raloxifene group · Postmenopausal women with osteoporosis | 600 mg | 400 IU | 1 year | — |
| Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis 2007 · Low-dose HRT group · Postmenopausal women with osteoporosis | 600 mg | 400 IU | 1 year | — |
| Effects of calcium and vitamin D supplementation on hip bone mineral density and calcium-related analytes in elderly ambulatory Australian women: a five-year randomized controlled trial 2008 · CaD group · Community-dwelling women aged 70–80 years | 1.2 g | 1,000 IU | 5 years | — |
| Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study 2008 · 2 mg IV ibandronate every 2 months · Women aged 55–80 years, at least 5 years postmenopause, with osteoporosis | 500 mg | 400 IU | 2 years | — |
| Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study 2008 · 3 mg IV ibandronate every 3 months · Women aged 55–80 years, at least 5 years postmenopause, with osteoporosis | 500 mg | 400 IU | 2 years | — |
| Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study 2008 · 2.5 mg daily oral ibandronate · Women aged 55–80 years, at least 5 years postmenopause, with osteoporosis | 500 mg | 400 IU | 2 years | — |
| Randomized controlled trial of the effects of calcium with or without vitamin D on bone structure and bone-related chemistry in elderly women with vitamin D insufficiency 2008 · Calcium plus vitamin D · Elderly women, mean age 77.2 years, with vitamin D insufficiency (serum 25(OH)D <60 nM) | 1 g | 1,000 IU | 1 year | — |
| Effect of vitamin D supplementation on wintertime and overall bone loss in healthy postmenopausal women 1991 · Vitamin D group · Healthy, ambulatory postmenopausal women with usual vitamin D intakes of 100 IU/day | 377 mg | 400 IU | 1 year | — |
| Effect of alendronate in elderly patients after low trauma hip fracture repair 2009 · Ca-Vit D group · Elderly patients after low-trauma hip fracture repair; mean age 81 ± 7 years; 79.8% women | 500 mg | 400 IU | 1 year | — |
| Effect of alendronate in elderly patients after low trauma hip fracture repair 2009 · ALN + Ca-Vit D group · Elderly patients after low-trauma hip fracture repair; mean age 81 ± 7 years; 79.8% women | 500 mg | 400 IU | 1 year | — |
| Effects of a multi-component exercise program and calcium-vitamin-D3-fortified milk on bone mineral density in older men: a randomised controlled trial 2009 · exercise + fortified milk · Men aged 50–79 years; older, well-nourished men | 1 g | 800 IU | 1 year | — |
| Effects of a multi-component exercise program and calcium-vitamin-D3-fortified milk on bone mineral density in older men: a randomised controlled trial 2009 · fortified milk · Men aged 50–79 years; older, well-nourished men | 1 g | 800 IU | 1 year | — |
| Biochemical markers of bone turnover associated with calcium supplementation in children with juvenile rheumatoid arthritis: results of a double-blind, placebo-controlled intervention trial 2008 · calcium supplementation group · Children aged 6–18 years with juvenile rheumatoid arthritis, without systemic corticosteroid therapy in the 3 months before enrollment | 1 g | 400 IU | 2 years | — |
| Vitamin D insufficiency does not affect response of bone mineral density to alendronate 2009 · Calcium and cholecalciferol recipients · Postmenopausal women with low bone mineral density | 500 mg | 250 IU | — | — |
| Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC 2009 · upfront zoledronic acid arm · Postmenopausal women with stage I–IIIa hormone receptor-positive breast cancer who had completed up to 6 years of tamoxifen and were starting letrozole | 1 g | — | 5 years | — |
| Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC 2009 · delayed zoledronic acid arm · Postmenopausal women with stage I–IIIa hormone receptor-positive breast cancer who had completed up to 6 years of tamoxifen and were starting letrozole | 1 g | — | 5 years | — |
| Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone 2009 · DHEA group · Men and women aged 65–75 years | 700 mg | 16 mcg | 2 years | — |
| Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone 2009 · Placebo group, then open-label DHEA in year 2 · Men and women aged 65–75 years | 700 mg | 16 mcg | 1 year | — |
| Phosphate and carbonate salts of calcium support robust bone building in osteoporosis 2010 · Tricalcium phosphate group · Patients with osteoporosis treated with teriparatide and consuming less than 1000 mg phosphorus per day | 1.8 g | 1,000 IU | 1 year | — |
| Phosphate and carbonate salts of calcium support robust bone building in osteoporosis 2010 · Calcium carbonate group · Patients with osteoporosis treated with teriparatide and consuming less than 1000 mg phosphorus per day | 1.8 g | 1,000 IU | 1 year | — |
| Additive impact of alfacalcidol on bone mineral density and bone strength in alendronate treated postmenopausal women with reduced bone mass 2011 · Alfa/ALN group · Postmenopausal women aged 73.6 ± 4.7 years with osteoporosis or osteopenia | 500 mg | — | 3 years | — |
| The effect of high-dose vitamin D on bone mineral density and bone turnover markers in postmenopausal women with low bone mass--a randomized controlled 1-year trial 2012 · high-dose vitamin D group · Postmenopausal women aged 50–80 years with reduced bone mass (BMD T-score ≤ −2.0 in the lumbar spine or total hip) | 1 g | — | 1 year | — |
| The effect of high-dose vitamin D on bone mineral density and bone turnover markers in postmenopausal women with low bone mass--a randomized controlled 1-year trial 2012 · standard-dose vitamin D group · Postmenopausal women aged 50–80 years with reduced bone mass (BMD T-score ≤ −2.0 in the lumbar spine or total hip) | 1 g | 800 IU | 1 year | — |
| Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis 2012 · Placebo group · Japanese postmenopausal women with osteoporosis | 600 mg | 400 IU | 1 year | — |
| Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis 2012 · Denosumab 14 mg group · Japanese postmenopausal women with osteoporosis | 600 mg | 400 IU | 1 year | — |
| Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis 2012 · Denosumab 60 mg group · Japanese postmenopausal women with osteoporosis | 600 mg | 400 IU | 1 year | — |
| Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis 2012 · Denosumab 100 mg group · Japanese postmenopausal women with osteoporosis | 600 mg | 400 IU | 1 year | — |
| Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study 1990 · calcitriol · Postmenopausal women with vertebral fractures; age range not reported | 600 mg | 0.62 mcg | 2 years | — |
| Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer 2012 · denosumab group · Men aged 70 years or older, or younger men with osteoporotic fracture history or low BMD, with nonmetastatic prostate cancer receiving androgen-deprivation therapy | 1 g | — | 3 years | — |
| Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer 2012 · placebo group · Men aged 70 years or older, or younger men with osteoporotic fracture history or low BMD, with nonmetastatic prostate cancer receiving androgen-deprivation therapy | 1 g | — | 3 years | — |
| A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation 2012 · Ibandronate group · Renal transplant recipients with early stable renal function | 1 g | 0.25 mcg | 1 year | — |
| A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation 2012 · Placebo group · Renal transplant recipients with early stable renal function | 1 g | 0.25 mcg | 1 year | — |
| Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis 2013 · low-dose ALN group · Chinese postmenopausal women aged 62.2 ± 7.0 years with osteopenia or osteoporosis | 600 mg | 125 IU | 1 year | — |
| Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis 2013 · standard-dose ALN group · Chinese postmenopausal women aged 62.2 ± 7.0 years with osteopenia or osteoporosis | 600 mg | 125 IU | 1 year | — |
| Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial 2013 · Control group · Adults aged 18 years or older with newly diagnosed lymphoma, without osteoporosis; vitamin D- or testosterone-deficient patients were eligible if receiving appropriate therapy | 1.2 g | — | 1 year | — |
| Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial 2013 · Zoledronic acid group · Adults aged 18 years or older with newly diagnosed lymphoma, without osteoporosis; vitamin D- or testosterone-deficient patients were eligible if receiving appropriate therapy | 1.2 g | — | 1 year | — |
| Vitamin D supplementation after parathyroidectomy: effect on bone mineral density-a randomized double-blind study 2014 · D+ · Adults with primary hyperparathyroidism after successful parathyroidectomy; median age 60 years, range 30–80; 79% women | 1 g | 1,600 IU | 1 year | — |
| Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial 2014 · Exemestane group · Postmenopausal women with early hormone-receptor-positive breast cancer, with baseline bone mineral density T-scores of either −2.0 or greater or less than −2.0 | 1 g | 800 IU | 2 years | — |
| Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial 2014 · Anastrozole group · Postmenopausal women with early hormone-receptor-positive breast cancer, with baseline bone mineral density T-scores of either −2.0 or greater or less than −2.0 | 1 g | 800 IU | 2 years | — |
| The effect of dried plum on serum levels of receptor activator of NF-κB ligand, osteoprotegerin and sclerostin in osteopenic postmenopausal women: a randomised controlled trial 2014 · 100 g dried plum/d group · Osteopenic postmenopausal women | 500 mg | 400 IU | 1 year | — |
| The effect of dried plum on serum levels of receptor activator of NF-κB ligand, osteoprotegerin and sclerostin in osteopenic postmenopausal women: a randomised controlled trial 2014 · 75 g dried apple/d comparative control group · Osteopenic postmenopausal women | 500 mg | 400 IU | 1 year | — |
| Effects of milk salt supplementation on bone mineral gain in pubertal Chinese adolescents: a 2-year randomized, double-blind, controlled, dose-response trial 2014 · Low-Ca group · Girls and boys aged 12–14 years | 300 mg | 200 IU | 2 years | — |
| Effects of milk salt supplementation on bone mineral gain in pubertal Chinese adolescents: a 2-year randomized, double-blind, controlled, dose-response trial 2014 · Mid-Ca group · Girls and boys aged 12–14 years | 600 mg | 200 IU | 2 years | — |
| Effects of milk salt supplementation on bone mineral gain in pubertal Chinese adolescents: a 2-year randomized, double-blind, controlled, dose-response trial 2014 · High-Ca group · Girls and boys aged 12–14 years | 600 mg | 200 IU | 2 years | — |
| A calcium-collagen chelate dietary supplement attenuates bone loss in postmenopausal women with osteopenia: a randomized controlled trial 2015 · CC group · Postmenopausal women with osteopenia | 500 mg | 200 IU | 1 year | — |
| A calcium-collagen chelate dietary supplement attenuates bone loss in postmenopausal women with osteopenia: a randomized controlled trial 2015 · Control group · Postmenopausal women with osteopenia | 500 mg | 200 IU | 1 year | — |
| Effects of strontium ranelate on bone mass and bone turnover in women with thalassemia major-related osteoporosis 2016 · SrR group · Women with thalassemia major-related osteoporosis | 1 g | 800 IU | 2 years | — |
| Effect of Growth Hormone Treatment on Fractures and Quality of Life in Postmenopausal Osteoporosis: A 10-Year Follow-Up Study 2015 · GH 1.0 U group · Women aged 50–70 with postmenopausal osteoporosis receiving estrogen hormone replacement | 750 mg | — | 3 years | — |
| Effect of Growth Hormone Treatment on Fractures and Quality of Life in Postmenopausal Osteoporosis: A 10-Year Follow-Up Study 2015 · GH 2.5 U group · Women aged 50–70 with postmenopausal osteoporosis receiving estrogen hormone replacement | 750 mg | — | 3 years | — |
| Effect of Milk Powder Supplementation with Different Calcium Contents on Bone Mineral Density of Postmenopausal Women in Northern China: A Randomized Controlled Double-Blind Trial 2016 · Group A · Postmenopausal women aged 50–65 years | 300 mg | 800 IU | 2 years | — |
| Effect of Milk Powder Supplementation with Different Calcium Contents on Bone Mineral Density of Postmenopausal Women in Northern China: A Randomized Controlled Double-Blind Trial 2016 · Group B · Postmenopausal women aged 50–65 years | 600 mg | 800 IU | 2 years | — |
| Effect of Milk Powder Supplementation with Different Calcium Contents on Bone Mineral Density of Postmenopausal Women in Northern China: A Randomized Controlled Double-Blind Trial 2016 · Group C · Postmenopausal women aged 50–65 years | 900 mg | 800 IU | 2 years | — |
| Primary hyperparathyroidism, hypercalciuria, and bone recovery after parathyroidectomy 2017 · Cholecalciferol and calcium carbonate · Adults with primary hyperparathyroidism undergoing parathyroidectomy; median age 60 years, 119 women | 1 g | 1,600 IU | 1 year | — |
| Oestrogen replacement improves bone mineral density in oligo-amenorrhoeic athletes: a randomised clinical trial 2019 · PATCH · Females aged 14–25 years with oligo-amenorrhoea who were endurance athletes; received the shared calcium and vitamin D supplementation alongside hormone treatment | 1.2 g | 800 IU | 1 year | — |
| Oestrogen replacement improves bone mineral density in oligo-amenorrhoeic athletes: a randomised clinical trial 2019 · PILL · Females aged 14–25 years with oligo-amenorrhoea who were endurance athletes; received the shared calcium and vitamin D supplementation alongside combined oral contraceptive treatment | 1.2 g | 800 IU | 1 year | — |
| Oestrogen replacement improves bone mineral density in oligo-amenorrhoeic athletes: a randomised clinical trial 2019 · NONE · Females aged 14–25 years with oligo-amenorrhoea who were endurance athletes; received the shared calcium and vitamin D supplementation and no oestrogen or progesterone | 1.2 g | 800 IU | 1 year | — |
| Role of Calcium and Low-Fat Dairy Foods in Weight-Loss Outcomes Revisited: Results from the Randomized Trial of Effects on Bone and Body Composition in Overweight/Obese Postmenopausal Women 2019 · Supplement group (S) · Overweight or obese Caucasian women 2–10 years postmenopausal, generally healthy, with dietary calcium intake of 800 mg/day or less | 630 mg | 400 IU | 26 weeks | — |
| Effect of Low-Dose Vitamin K2 Supplementation on Bone Mineral Density in Middle-Aged and Elderly Chinese: A Randomized Controlled Study 2020 · Co-supplementation group · Community-dwelling men and postmenopausal women aged 50–75 years | 500 mg | 10 mcg | 1 year | — |
| The effect of vitamin MK-7 on bone mineral density and microarchitecture in postmenopausal women with osteopenia, a 3-year randomized, placebo-controlled clinical trial 2021 · vitamin K2 (MK-7) group · Postmenopausal women with osteopenia | 800 mg | 38 mcg | 1096 days | — |
| The effect of vitamin MK-7 on bone mineral density and microarchitecture in postmenopausal women with osteopenia, a 3-year randomized, placebo-controlled clinical trial 2021 · Placebo group · Postmenopausal women with osteopenia | 800 mg | 38 mcg | 1096 days | — |
| Impact of Vitamin D and Calcium Supplementation on Bone Mineral Density and Bone Metabolism Among Thai Adolescents With Perinatally Acquired Human Immunodeficiency Virus (HIV) Infection: A Randomized Clinical Trial 2021 · standard-dose VitD/Ca supplementation · Adolescents aged 10–20 years with perinatally acquired HIV who were on stable cART | 1.2 g | 400 IU | 48 weeks | — |
| Impact of Vitamin D and Calcium Supplementation on Bone Mineral Density and Bone Metabolism Among Thai Adolescents With Perinatally Acquired Human Immunodeficiency Virus (HIV) Infection: A Randomized Clinical Trial 2021 · high-dose VitD/Ca supplementation · Adolescents aged 10–20 years with perinatally acquired HIV who were on stable cART | 1.2 g | 3,257 IU | 48 weeks | — |
| Effect of Calcium and Vitamin D Supplementation With and Without Collagen Peptides on Volumetric and Areal Bone Mineral Density, Bone Geometry and Bone Turnover in Postmenopausal Women With Osteopenia 2022 · Group A · Postmenopausal women with osteopenia | 500 mg | 400 IU | 1 year | — |
| High-dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT 2024 · Arm 2 (placebo arm; daily supplements) · Men aged 60 years or older with stage I–IV prostate cancer, no bone metastases, receiving androgen deprivation therapy, and serum 25(OH)D below 32 ng/mL | 1.01 g | 800 IU | 24 weeks | — |
| Impact of high-dose vitamin D and calcium carbonate supplementation on bone density in adolescents living with HIV: a randomised, placebo-controlled trial 2026 · intervention · Adolescents aged 11–19 years with perinatally acquired HIV, taking antiretroviral therapy | 500 mg | 2,857 IU | 48 weeks | — |
| Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin 1993 · Calcitriol plus salmon calcitonin · Patients starting long-term corticosteroid therapy | 1 g | — | 1 year | — |
| Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin 1993 · Calcitriol plus placebo nasal spray · Patients starting long-term corticosteroid therapy | 1 g | — | 1 year | — |
| Rates of bone loss in postmenopausal women randomly assigned to one of two dosages of vitamin D 1995 · 2.5 micrograms (100 IU) vitamin D/d group · Healthy ambulatory postmenopausal women | 500 mg | 100 IU | 2 years | — |
| Rates of bone loss in postmenopausal women randomly assigned to one of two dosages of vitamin D 1995 · 17.5 micrograms (700 IU) vitamin D/d group · Healthy ambulatory postmenopausal women | 500 mg | 700 IU | 2 years | — |
| Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss 1994 · calcium augmentation · Healthy white women 3 to 6 years after spontaneous menopause | 1.7 g | 400 IU | 1059 days | — |
| Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss 1994 · estrogen-progesterone-calcium · Healthy white women 3 to 6 years after spontaneous menopause | 1.7 g | 400 IU | 1059 days | — |
| Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial 1996 · Calcium carbonate and vitamin D3 · Patients with rheumatoid arthritis; some were receiving corticosteroids and some were not | 1 g | 500 IU | 2 years | — |
| Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older 1997 · calcium and vitamin D group · Men and women 65 years of age or older living at home | 500 mg | 700 IU | 3 years | — |
| Calcium and vitamin D supplementation increases spinal BMD in healthy, postmenopausal women 1998 · Calcium and vitamin D supplement group · Healthy postmenopausal women aged 58–67 | 1 g | — | 2 years | — |
| [Vitrum osteomag in prevention of osteoporosis in postmenopausal women: results of the comparative open multicenter trial] 2004 · Group 1: Vitrum Osteomag · Postmenopausal women with osteopenia; age range not reported | 1.2 g | 400 IU | 1 year | 125 |
| Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial 2018 · VITD3 group · Youth aged 16–24 years with HIV, RNA load <200 copies/mL, taking TDF-containing combination antiretroviral therapy for at least 180 days | 162 mg | — | 48 weeks | 109 |
| Calcium and vitamin D fortified milk reduces bone turnover and improves bone density in postmenopausal women over 1 year 2018 · intervention · Chinese postmenopausal women in Malaysia; mean age 59 years | 1.2 g | 15 mcg | 1 year | 61 |
| Effect of a combination of genistein, polyunsaturated fatty acids and vitamins D3 and K1 on bone mineral density in postmenopausal women: a randomized, placebo-controlled, double-blind pilot study 2013 · geniVida bone blend (GBB) · Healthy postmenopausal women aged 45–55 years, 1–3 years since their last spontaneous menstrual bleeding | 500 mg | 800 IU | 26 weeks | 31 |
| The Impact of Vitamin D, Calcium, Protein Supplementation, and Physical Exercise on Bone Metabolism After Bariatric Surgery: The BABS Study 2016 · intervention group · Women and similarly aged men with BMI >38 kg/m² after Roux-en-Y gastric bypass or sleeve gastrectomy; median age 40.7 years | 1 g | 6,286 IU | 2 years | — |
| High-dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT 2024 · Arm 1 (high-dose vitamin D) · Men aged 60 years or older with stage I–IV prostate cancer, no bone metastases, receiving androgen deprivation therapy, and serum 25(OH)D below 32 ng/mL | 1.01 g | 7,943 IU | 24 weeks | — |
| Effect of a single-dose denosumab on mineral homeostasis in infertile men: insights from a pilot intervention study and a randomized controlled trial 2025 · Randomized trial, denosumab group · Infertile men; mean age approximately 34 years | 400 mg | 25 mcg | 160 days | 49 |
| Long-term effects of giving nursing home residents bread fortified with 125 microg (5000 IU) vitamin D(3) per daily serving 2009 · Vitamin D- and calcium-fortified bun · Older nursing home residents; sex and age range not reported; vitamin D-deficient | 320 mg | 125 mcg | 1 year | 45 |
| Comparison of the absorption of calcium carbonate and calcium citrate after Roux-en-Y gastric bypass 2009 · calcium citrate phase · Adults aged 30–61 years who had undergone Roux-en-Y gastric bypass approximately 1 year earlier; 17 women and 1 man | 500 mg | 62.5 IU | 1 day | 18 |
| Comparison of the absorption of calcium carbonate and calcium citrate after Roux-en-Y gastric bypass 2009 · calcium carbonate phase · Adults aged 30–61 years who had undergone Roux-en-Y gastric bypass approximately 1 year earlier; 17 women and 1 man | 500 mg | 125 IU | 1 day | 18 |
| Vitamin D2 dose required to rapidly increase 25OHD levels in osteoporotic women 2006 · 125 microg/day vitamin D(2) group · Postmenopausal women with osteopenia or osteoporosis; median age 61.5 years | 500 mg | 125 mcg | 90 days | 13 |
| Vitamin D2 dose required to rapidly increase 25OHD levels in osteoporotic women 2006 · 250 microg/day vitamin D(2) group · Postmenopausal women with osteopenia or osteoporosis; median age 61.5 years | 500 mg | 250 mcg | 90 days | 12 |
| Green tea polyphenols supplementation and Tai Chi exercise for postmenopausal osteopenic women: safety and quality of life report 2010 · GTP group · Postmenopausal women with osteopenia; at least 2 years after menopause | 500 mg | 200 IU | 24 weeks | 47 |
| Green tea polyphenols supplementation and Tai Chi exercise for postmenopausal osteopenic women: safety and quality of life report 2010 · Placebo + TC group · Postmenopausal women with osteopenia; at least 2 years after menopause | 500 mg | 200 IU | 24 weeks | 42 |
| Green tea polyphenols supplementation and Tai Chi exercise for postmenopausal osteopenic women: safety and quality of life report 2010 · GTP + TC group · Postmenopausal women with osteopenia; at least 2 years after menopause | 500 mg | 200 IU | 24 weeks | 38 |
| Effect of a single-dose denosumab on mineral homeostasis in infertile men: insights from a pilot intervention study and a randomized controlled trial 2025 · Pilot cohort · Infertile men; mean age 33.4 years | 400 mg | 25 mcg | 270 days | 12 |
| Calcium absorption in postmenopausal osteoporosis: benefit of HRT plus calcitriol, but not HRT alone, in both malabsorbers and normal absorbers 2000 · HRT plus calcitriol · Postmenopausal women with osteoporosis and vertebral compression fractures; age not reported | 600 mg | — | 243 days | — |
| Combined calcium and vitamin D supplementation is not superior to calcium supplementation alone in improving disturbed bone metabolism in patients with congestive heart failure 2008 · CaD group · Ambulatory men with congestive heart failure, low vitamin D status, and insufficient dietary calcium intake | 500 mg | 50 mcg | 270 days | — |
| [Changes of serum lipids after soy isoflavone and calcium supplementation in postmenopausal Chinese women with different ER-beta genotypes] 2011 · group I · Postmenopausal Chinese women with normal serum lipids and bone loss or osteoporosis | 440 mg | 100 IU | 1 year | — |
| Effect of green tea and Tai Chi on bone health in postmenopausal osteopenic women: a 6-month randomized placebo-controlled trial 2012 · Placebo · Postmenopausal women with osteopenia | 500 mg | 200 IU | 26 weeks | — |
| Effect of green tea and Tai Chi on bone health in postmenopausal osteopenic women: a 6-month randomized placebo-controlled trial 2012 · GTP · Postmenopausal women with osteopenia | 500 mg | 200 IU | 26 weeks | — |
| Effect of green tea and Tai Chi on bone health in postmenopausal osteopenic women: a 6-month randomized placebo-controlled trial 2012 · Placebo + TC · Postmenopausal women with osteopenia | 500 mg | 200 IU | 26 weeks | — |
| Effect of green tea and Tai Chi on bone health in postmenopausal osteopenic women: a 6-month randomized placebo-controlled trial 2012 · GTP + TC · Postmenopausal women with osteopenia | 500 mg | 200 IU | 26 weeks | — |
| Calcium plus vitamin D supplementation during pregnancy has no impact on postpartum transient longitudinal changes in hip geometry in adolescent mothers: a secondary analysis of a randomised controlled trial 2024 · calcium plus vitamin D · Pregnant adolescents aged 14–19 years with low daily calcium intake (approximately 600 mg/day); lactating postpartum adolescents were assessed | 600 mg | 200 mcg | — | — |
| SNP rs11185644 of RXRA gene is identified for dose-response variability to vitamin D3 supplementation: a randomized clinical trial 2017 · D&Cancer Ca + D group · Postmenopausal non-Hispanic white women aged 55 years or older, in good general health | 1.5 g | 2,000 IU | 1 year | 915 |
| Correction of vitamin D insufficiency with combined strontium ranelate and vitamin D3 in osteoporotic patients 2014 · strontium ranelate 2 g/vitamin D₃ 1000 IU daily · Men and postmenopausal women aged 50 years or older with primary osteoporosis and serum 25(OH)D >22.5 nmol/l | 1 g | 1,000 IU | 26 weeks | 413 |
| Does Vitamin D3 Supplementation Improve Depression Scores among Rural Adolescents? A Randomized Controlled Trial 2024 · calcium intervention arm · Rural adolescent boys and girls aged 14–19 years with any form of depression | 500 mg | 250 IU | 9 weeks | 216 |
| SNP rs11185644 of RXRA gene is identified for dose-response variability to vitamin D3 supplementation: a randomized clinical trial 2017 · CaMEWS Ca + D group · Postmenopausal non-Hispanic white women aged 55 years or older, in good general health | 1.5 g | 1,100 IU | 1 year | 203 |
| Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study 2002 · calcium-vitamin D3 fixed combination group · Ambulatory institutionalized women; mean age 85.2 years; vitamin D insufficiency and low calcium intake described in the study population | 1.2 g | 800 IU | 2 years | 199 |
| Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study 2002 · calcium plus vitamin D3 separate combination group · Ambulatory institutionalized women; mean age 85.2 years; vitamin D insufficiency and low calcium intake described in the study population | 1.2 g | 800 IU | 2 years | 190 |
| Type of dietary fat is associated with the 25-hydroxyvitamin D3 increment in response to vitamin D supplementation 2011 · active treatment arm · Healthy men and women aged 65 and older | 500 mg | 700 IU | 2 years | 152 |
| Body size and serum 25 hydroxy vitamin D response to oral supplements in healthy older adults 2008 · calcium-vitamin D supplementation treatment group · Men and women aged 65 years or older; healthy and ambulatory | 500 mg | 700 IU | 3 years | 132 |
| Time out: should vitamin D dosing be based on patient's body mass index (BMI): a prospective controlled study 2021 · Group A (2000 IU) · Women with vitamin D deficiency and BMI ≥30 kg/m²; mean age 50 years; treated in orthopaedic, obstetrics and gynaecology clinics | 600 mg | 2,000 IU | 90 days | 121 |
| Calcifediol (25-hydroxyvitamin D) improvement and calcium-phosphate metabolism of alendronate sodium/vitamin D(3) combination in Chinese women with postmenopausal osteoporosis: a post hoc efficacy analysis and safety reappraisal 2018 · ALN/D5600 · Postmenopausal women in China aged over 55 with postmenopausal osteoporosis | 500 mg | 800 IU | 1 year | 111 |
| Vitamin D3 Dose Requirement That Raises 25-Hydroxyvitamin D to Desirable Level in Overweight and Obese Elderly 2021 · Low dose (600 IU/day) · Lebanese women and men aged 65 years or older who were overweight or obese and had baseline serum 25(OH)D of 10–30 ng/mL | 1 g | 600 IU | 1 year | 111 |
| Vitamin D3 Dose Requirement That Raises 25-Hydroxyvitamin D to Desirable Level in Overweight and Obese Elderly 2021 · High dose (3750 IU/day) · Lebanese women and men aged 65 years or older who were overweight or obese and had baseline serum 25(OH)D of 10–30 ng/mL | 1 g | 3,750 IU | 1 year | 110 |
| Time out: should vitamin D dosing be based on patient's body mass index (BMI): a prospective controlled study 2021 · Group B (125 IU/kg/m²) · Women with vitamin D deficiency and BMI ≥30 kg/m²; mean age 52 years; treated in orthopaedic, obstetrics and gynaecology clinics | 600 mg | — | 90 days | 109 |
| Response of serum 25(OH)D to Vitamin D and calcium supplementation in school-children from a semi-rural setting in India 2018 · Daily vitamin D and calcium supplementation · Schoolchildren aged 6–12 years, boys and girls, from a semi-rural setting in India; baseline vitamin D status varied | 500 mg | 1,000 IU | 26 weeks | 106 |
| Randomised Controlled Trial Comparing Daily Versus Depot Vitamin D3 Therapy in 0-16-Year-Old Newly Settled Refugees in Western Australia Over a Period of 40 Weeks 2018 · depot therapy · Refugee children aged 5.5 months to 16 years with serum 25(OH)D below 78 nmol/L | 200 mg | — | 40 weeks | 84 |
| Randomised Controlled Trial Comparing Daily Versus Depot Vitamin D3 Therapy in 0-16-Year-Old Newly Settled Refugees in Western Australia Over a Period of 40 Weeks 2018 · daily therapy · Refugee children aged 5.5 months to 16 years with serum 25(OH)D below 78 nmol/L | 200 mg | — | 40 weeks | 73 |
| A randomized, double-blind, placebo-controlled trial of vitamin D supplementation with or without calcium in community-dwelling vitamin D deficient subjects 2022 · Vitamin D3 + Calcium · Adults aged 18 years and over, men and women, with vitamin D deficiency; apparently healthy community-dwelling UAE residents and expatriates | 600 mg | 2,000 IU | 26 weeks | 68 |
| Impact of vitamin D supplementation during lactation on vitamin D status and body composition of mother-infant pairs: a MAVID randomized controlled trial 2014 · 400 IU/d group · Caucasian lactating mothers who delivered a healthy term infant and intended to breastfeed for 6 months | 200 mg | 400 IU | 26 weeks | 67 |
| Regular consumption of vitamin D-fortified yogurt drink (Doogh) improved endothelial biomarkers in subjects with type 2 diabetes: a randomized double-blind clinical trial 2011 · vitamin D3-fortified doogh (FYD) · Adults aged 29–67 years with type 2 diabetes; 57 women and 43 men overall | 340 mg | 1,000 IU | 12 weeks | 50 |
| Improvement of vitamin D status resulted in amelioration of biomarkers of systemic inflammation in the subjects with type 2 diabetes 2012 · vitamin D3-fortified doogh (FD) · People with type 2 diabetes | 340 mg | 1,000 IU | 12 weeks | 50 |
| Daily vs. monthly oral vitamin D(3) for treatment of symptomatic vitamin D deficiency in infants: a randomized controlled trial 2023 · Daily (D) group · Infants with symptomatic vitamin D deficiency | 50 mg/kg | 2,000 IU | 90 days | 46 |
| Evaluation of a new solid formulation of calcium and vitamin D in institutionalized elderly subjects. A randomized comparative trial versus separate administration of both constituents 1995 · G1 · Institutionalized elderly subjects, mean age 83.1 years, with vitamin D deficiency and without severe renal failure | 1 g | 800 IU | 26 weeks | 46 |
| Evaluation of a new solid formulation of calcium and vitamin D in institutionalized elderly subjects. A randomized comparative trial versus separate administration of both constituents 1995 · G2 · Institutionalized elderly subjects, mean age 83.1 years, with vitamin D deficiency and without severe renal failure | 1 g | 800 IU | 26 weeks | 45 |
| Daily vs. monthly oral vitamin D(3) for treatment of symptomatic vitamin D deficiency in infants: a randomized controlled trial 2023 · Bolus (B) group · Infants with symptomatic vitamin D deficiency | 50 mg/kg | — | 90 days | 44 |
| Daily versus fortnightly oral vitamin D(3) in treatment of symptomatic vitamin D deficiency in children aged 1-10 years: An open labelled randomized controlled trial 2024 · group daily (D) · Children aged 1–10 years with symptomatic vitamin D deficiency | 500 mg | 4,000 IU | 12 weeks | 40 |
| Daily versus fortnightly oral vitamin D(3) in treatment of symptomatic vitamin D deficiency in children aged 1-10 years: An open labelled randomized controlled trial 2024 · group bolus (B) · Children aged 1–10 years with symptomatic vitamin D deficiency | 500 mg | — | 12 weeks | 40 |
| Effects of Vitamin D3 Supplementation and Resistance Training on 25-Hydroxyvitamin D Status and Functional Performance of Older Adults: A Randomized Placebo-Controlled Trial 2021 · vitamin D3 monthly group (VDM) · Adults aged 65–85 years, community-dwelling, with low-to-moderate baseline vitamin D levels; independent lifestyle | 400 mg | — | 14 weeks | 37 |
| Treatment of vitamin D depletion after Roux-en-Y gastric bypass: a randomized prospective clinical trial 2009 · group 1 · Morbidly obese women with vitamin D depletion after Roux-en-Y gastric bypass | 1.5 g | 7,943 IU | 1 year | 30 |
| Treatment of vitamin D depletion after Roux-en-Y gastric bypass: a randomized prospective clinical trial 2009 · group 2 · Morbidly obese women with vitamin D depletion after Roux-en-Y gastric bypass | 1.5 g | 800 IU | 1 year | 30 |
| Effects of Vitamin D3 Supplementation and Resistance Training on 25-Hydroxyvitamin D Status and Functional Performance of Older Adults: A Randomized Placebo-Controlled Trial 2021 · vitamin D3 daily group (VDD) · Adults aged 65–85 years, community-dwelling, with low-to-moderate baseline vitamin D levels; independent lifestyle | 400 mg | 800 IU | 14 weeks | 30 |
| Effect of bimonthly supplementation with oral cholecalciferol on serum 25-hydroxyvitamin D concentrations in HIV-infected children and adolescents 2009 · VD+ · HIV-infected children and adolescents aged 6–16 years | 1 g | — | 1 year | 29 |
| Fortification of Yogurts with Vitamin D and Calcium Enhances the Inhibition of Serum Parathyroid Hormone and Bone Resorption Markers: A Double Blind Randomized Controlled Trial in Women over 60 Living in a Community Dwelling Home 2015 · Fortified Yogurt (FY) · Women aged 61–90 with serum 25OHD ≤20 ng/mL, living in community sheltered accommodation | 520 mg | 10 mcg | 12 weeks | 28 |
| Calcium plus vitamin D supplementation affects glucose metabolism and lipid concentrations in overweight and obese vitamin D deficient women with polycystic ovary syndrome 2015 · 1000 mg calcium/d + 50,000 IU/wk vitamin D · Overweight and obese vitamin D deficient women diagnosed with PCOS | 1 g | 7,143 IU | 8 weeks | 26 |
| Vitamin D supplementation and calcium absorption during caloric restriction: a randomized double-blind trial 2013 · weight loss and placebo · Postmenopausal women with 25(OH)D concentrations <70 nmol/L assigned to weight loss | 1.2 g | 10 mcg | 6 weeks | 22 |
| Effects of vitamin D3 and calcium supplementation on serum levels of tocopherols, retinol, and specific vitamin D metabolites 2012 · calcium plus vitamin D3 · Adults aged 30–75 in general health with a history of at least one pathology-confirmed adenomatous colorectal polyp within the previous 36 months | 2 g | 800 IU | 26 weeks | 21 |
| Vitamin D supplementation and calcium absorption during caloric restriction: a randomized double-blind trial 2013 · weight maintenance and placebo · Postmenopausal women with 25(OH)D concentrations <70 nmol/L assigned to weight maintenance | 1.2 g | 10 mcg | 6 weeks | 21 |
| Vitamin D supplementation and calcium absorption during caloric restriction: a randomized double-blind trial 2013 · weight maintenance and vitamin D3-supplementation (WM-D) · Postmenopausal women with 25(OH)D concentrations <70 nmol/L assigned to weight maintenance | 1.2 g | 63.6 mcg | 6 weeks | 20 |
| Changes in circulating 25-hydroxyvitamin D according to vitamin D binding protein genotypes after vitamin D₃ or D₂supplementation 2013 · Vitamin D3 group · Healthy adults aged 15–70 years, both sexes; some had vitamin D deficiency | 675 mg | 400 IU | 90 days | 20 |
| Vitamin D supplementation and calcium absorption during caloric restriction: a randomized double-blind trial 2013 · weight loss and vitamin D3-supplementation (WL-D) · Postmenopausal women with 25(OH)D concentrations <70 nmol/L assigned to weight loss | 1.2 g | 63.6 mcg | 6 weeks | 19 |
| Changes in circulating 25-hydroxyvitamin D according to vitamin D binding protein genotypes after vitamin D₃ or D₂supplementation 2013 · Vitamin D2 group · Healthy adults aged 15–70 years, both sexes; some had vitamin D deficiency | 500 mg | 400 IU | 90 days | 19 |
| Impact of Omega-3 and Vitamin D Supplementation on Bone Turnover Markers in Children with Leukemia: Follow-Up During and After Supplementation 2025 · VDCa group · Children aged 5–17 years with acute lymphoblastic leukemia in the maintenance phase | 1 g | 4,000 IU | 6 weeks | 17 |
| Narrowband ultraviolet B three times per week is more effective in treating vitamin D deficiency than 1600 IU oral vitamin D₃ per day: a randomized clinical trial 2012 · oral vitamin D(3) and calcium group · Participants with vitamin D deficiency (25(OH)D(3) ≤ 25 nmol L(-1)); age and sex not reported | 1 g | 1,600 IU | 6 weeks | 16 |
| Absorption of silicon from artesian aquifer water and its impact on bone health in postmenopausal women: a 12 week pilot study 2010 · Silicon-rich Water (SW) · Postmenopausal women within 5 years of menopause with reduced bone density but no osteopenia or osteoporosis by DEXA | 1.2 g | 800 IU | 14 weeks | 10 |
| Calcium and vitamin D intakes in children: a randomized controlled trial 2013 · Group 1 (dietary counseling plus Ca and Vitamin D supplementation) · Children aged 9.7–11.4 years with dietary calcium and vitamin D intake below 70% of the recommended intake | 400 mg | 400 IU | 120 days | 10 |
| Absorption of silicon from artesian aquifer water and its impact on bone health in postmenopausal women: a 12 week pilot study 2010 · Purified Water (PW) · Postmenopausal women within 5 years of menopause with reduced bone density but no osteopenia or osteoporosis by DEXA | 1.2 g | 800 IU | 14 weeks | 9 |
| A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: The Nottingham Neck of Femur (NONOF) Study 2004 · injected vitamin D(2) plus oral calcium · elderly women recruited after surgery for hip fracture | 1 g | — | 1 year | — |
| A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: The Nottingham Neck of Femur (NONOF) Study 2004 · oral vitamin D(3) plus calcium · elderly women recruited after surgery for hip fracture | 1 g | — | 1 year | — |
| Lack of effect of calcium intake on the 25-hydroxyvitamin d response to oral vitamin D3 2005 · Calcium group · Healthy older men and women | 1 g | 800 IU | 90 days | — |
| Which therapy to prevent post-thyroidectomy hypocalcemia? 2005 · group B · Patients undergoing total thyroidectomy for benign thyroid disease or malignancy; age and sex not specified | 1.5 g | — | — | — |
| Effect of vitamin D supplementation on vitamin D status and bone turnover markers in young adults 2006 · vitamin D group · Healthy university students aged 18–27 years, male and female | 1.5 g | 15 mcg | 8 weeks | — |
| Vitamin D supplementation has minor effects on parathyroid hormone and bone turnover markers in vitamin D-deficient bedridden older patients 2008 · Group II (400 IU cholecalciferol per day) · Long-term inpatients aged over 65 years who were chronically bedridden; vitamin D deficiency was prevalent | 500 mg | 400 IU | 26 weeks | — |
| Vitamin D supplementation has minor effects on parathyroid hormone and bone turnover markers in vitamin D-deficient bedridden older patients 2008 · Group III (1200 IU cholecalciferol per day) · Long-term inpatients aged over 65 years who were chronically bedridden; vitamin D deficiency was prevalent | 500 mg | 1,200 IU | 26 weeks | — |
| Treatment of hypovitaminosis D in infants and toddlers 2008 · Vitamin D2 daily · Infants and toddlers with hypovitaminosis D; exact age range and sex not reported | 50 mg/kg | 2,000 IU | 6 weeks | — |
| Treatment of hypovitaminosis D in infants and toddlers 2008 · Vitamin D2 weekly · Infants and toddlers with hypovitaminosis D; exact age range and sex not reported | 50 mg/kg | 7,143 IU | 6 weeks | — |
| Treatment of hypovitaminosis D in infants and toddlers 2008 · Vitamin D3 daily · Infants and toddlers with hypovitaminosis D; exact age range and sex not reported | 50 mg/kg | 2,000 IU | 6 weeks | — |
| The effect of a single dose versus a daily dose of cholecalciferol on the serum 25-hydroxycholecalciferol and parathyroid hormone levels in the elderly with secondary hyperparathyroidism living in a low-income housing unit 2008 · group 1 · Adults aged 65–102 years with secondary hyperparathyroidism and normal or reduced serum calcium, living in a low-income housing unit | 1.25 g | 300,000 IU | 39 weeks | — |
| The effect of a single dose versus a daily dose of cholecalciferol on the serum 25-hydroxycholecalciferol and parathyroid hormone levels in the elderly with secondary hyperparathyroidism living in a low-income housing unit 2008 · group 2 · Adults aged 65–102 years with secondary hyperparathyroidism and normal or reduced serum calcium, living in a low-income housing unit | 1.25 g | 800 IU | 39 weeks | — |
| Effect of vitamin D supplementation in the institutionalized elderly 2009 · group (B) · Institutionalized elderly with low baseline vitamin D status | 200 mg | 5 mcg | 30 days | — |
| The same annual dose of 292000 IU of vitamin D (cholecalciferol) on either daily or four monthly basis for elderly women: 1-year comparative study of the effects on serum 25(OH)D concentrations and renal function 2010 · D group · Women aged 69.3–78.8 years | 1 g | 800 IU | 1 year | — |
| The same annual dose of 292000 IU of vitamin D (cholecalciferol) on either daily or four monthly basis for elderly women: 1-year comparative study of the effects on serum 25(OH)D concentrations and renal function 2010 · 4 M group · Women aged 69.3–78.8 years | 1 g | — | 1 year | — |
| Is a lower dose of vitamin D supplementation enough to increase 25(OH)D status in a sunny country? 2010 · supplement group · Postmenopausal women with osteoporosis, mean age 62 ± 8 years | 1.2 g | 400 IU | 90 days | — |
| Improvement of vitamin D status in Japanese institutionalized elderly by supplementation with 800 IU of vitamin D(3) 2009 · Ca+VD group · Institutionalized elderly; age and sex not specified; baseline serum 25-hydroxyvitamin D was in the hypovitaminosis D range | 200 mg | 800 IU | 30 days | — |
| Effect of vitamin D, calcium and multiple micronutrient supplementation on vitamin D and bone status in Bangladeshi premenopausal garment factory workers with hypovitaminosis D: a double-blinded, randomised, placebo-controlled 1-year intervention 2010 · VD and Ca (VD-Ca) group · Females aged 16–36 years working in garment factories in Bangladesh with hypovitaminosis D | 600 mg | 10 mcg | 1 year | — |
| Effect of vitamin D, calcium and multiple micronutrient supplementation on vitamin D and bone status in Bangladeshi premenopausal garment factory workers with hypovitaminosis D: a double-blinded, randomised, placebo-controlled 1-year intervention 2010 · Multiple micronutrient and Ca (MMN-Ca) group · Females aged 16–36 years working in garment factories in Bangladesh with hypovitaminosis D | 600 mg | 10 mcg | 1 year | — |
| Vitamin D status and impact of vitamin D3 and/or calcium supplementation in a randomized pilot study in the Southeastern United States 2009 · 2,000 mg calcium plus 800 IU vitamin D daily · Adults aged 30–74 with a history of at least one pathologically confirmed adenomatous colonic polyp within the previous 36 months | 2 g | 800 IU | 26 weeks | — |
| Efficacy and safety of oral continuous low-dose versus short-term high-dose vitamin D: a prospective randomised trial conducted in a clinical setting 2010 · high-dose regimen · Vitamin D-deficient inpatients with serum 25(OH)D ≤ 50 nmol/L | 500 mg | 50,000 IU | 10 days | — |
| Efficacy and safety of oral continuous low-dose versus short-term high-dose vitamin D: a prospective randomised trial conducted in a clinical setting 2010 · continuous low-dose regimen · Vitamin D-deficient inpatients with serum 25(OH)D ≤ 50 nmol/L | 500 mg | 4,000 IU | 90 days | — |
| Is a daily supplementation with 40 microgram vitamin D3 sufficient? A randomised controlled trial 2012 · vitamin D(3) plus calcium group · Community-dwelling adults aged 55–84 years | 1 g | 40 mcg | 1 year | — |
| Changes in vitamin D metabolites during teriparatide treatment 2012 · teriparatide group · postmenopausal women and men with osteoporosis | 1 g | — | 1 year | — |
| Changes in vitamin D metabolites during teriparatide treatment 2012 · placebo group · postmenopausal women and men with osteoporosis | 1 g | — | 1 year | — |
| The necessity and safety of calcium and vitamin D in the elderly 1990 · Treatment group, independently living elderly women · Independently living elderly women | 1.56 g | 45 mcg | 11 weeks | — |
| The necessity and safety of calcium and vitamin D in the elderly 1990 · Treatment group, institutionalized elderly women · Institutionalized elderly women | 1.56 g | 45 mcg | 11 weeks | — |
| Multinutrient-fortified juices improve vitamin D and vitamin E status in children: a randomized controlled trial 2014 · CaD · Children aged approximately 8 years | 700 mg | 200 IU | 12 weeks | — |
| Calcium-vitamin D-fortified milk is as effective on circulating bone biomarkers as fortified juice and supplement but has less acceptance: a randomised controlled school-based trial 2014 · supplement · Children aged 9–12 years, both sexes, in Tehran | 500 mg | 200 IU | 12 weeks | — |
| How well are the optimal serum 25OHD concentrations reached in high-dose intermittent vitamin D therapy? a placebo-controlled study on comparison between 100 000 IU and 200 000 IU of oral D3 every 3 months in elderly women 2016 · 100 000 IU vitamin D3 group (group 1D) · Women aged about 75 years receiving intermittent vitamin D therapy | 1 g | — | 1 year | — |
| How well are the optimal serum 25OHD concentrations reached in high-dose intermittent vitamin D therapy? a placebo-controlled study on comparison between 100 000 IU and 200 000 IU of oral D3 every 3 months in elderly women 2016 · 200 000 IU vitamin D3 group (2D) · Women aged about 75 years receiving intermittent vitamin D therapy | 1 g | — | 1 year | — |
| Association Between Single Gene Polymorphisms and Bone Biomarkers and Response to Calcium and Vitamin D Supplementation in Young Adults Undergoing Military Training 2017 · calcium and vitamin D · Young adults undergoing Army or Air Force initial military training | 2 g | 1,000 IU | 9 weeks | — |
| A randomized controlled trial testing an adherence-optimized Vitamin D regimen to mitigate bone change in adolescents being treated for acute lymphoblastic leukemia 2017 · Initial daily Vitamin D3 + calcium citrate formulation · Adolescents aged 10–21 years with newly diagnosed B-ALL or T-ALL and Vitamin D insufficiency or deficiency | 1 g | 2,000 IU | — | — |
| A randomized controlled trial testing an adherence-optimized Vitamin D regimen to mitigate bone change in adolescents being treated for acute lymphoblastic leukemia 2017 · DOT Vitamin D3 intervention · Adolescents aged 10–21 years with newly diagnosed B-ALL or T-ALL and Vitamin D insufficiency or deficiency | 800 mg | — | 204 days | — |
| Racial differences in calculated bioavailable vitamin D with vitamin D/calcium supplementation 2017 · VitD/Ca arm · HIV-infected, ART-naive participants with 25-(OH)D ≥10 and <75 ng/mL, CrCl ≥60 mL/min, and serum calcium <10.5 mg/dL; age and sex not specified | 1 g | 4,000 IU | 48 weeks | — |
| Treatment of vitamin D deficiency in Chinese inflammatory bowel disease patients: A prospective, randomized, open-label, pilot study 2018 · arm A · Chinese adults with ulcerative colitis or Crohn's disease and vitamin D insufficiency or deficiency | 600 mg | — | 1 year | — |
| A PROSPECTIVE STUDY OF COMMONLY UTILIZED REGIMENS OF VITAMIN D REPLACEMENT AND MAINTENANCE THERAPY IN ADULTS 2019 · D3 2,000 IU daily · Adults aged 25–85 years with 25(OH)D below 30 ng/mL | 500 mg | 2,000 IU | 1 year | — |
| A PROSPECTIVE STUDY OF COMMONLY UTILIZED REGIMENS OF VITAMIN D REPLACEMENT AND MAINTENANCE THERAPY IN ADULTS 2019 · D3 3,000 IU daily · Adults aged 25–85 years with 25(OH)D below 30 ng/mL | 500 mg | 3,000 IU | 1 year | — |
| A PROSPECTIVE STUDY OF COMMONLY UTILIZED REGIMENS OF VITAMIN D REPLACEMENT AND MAINTENANCE THERAPY IN ADULTS 2019 · D2 50,000 IU weekly · Adults aged 25–85 years with 25(OH)D below 30 ng/mL | 500 mg | 7,143 IU | 1 year | — |
| A PROSPECTIVE STUDY OF COMMONLY UTILIZED REGIMENS OF VITAMIN D REPLACEMENT AND MAINTENANCE THERAPY IN ADULTS 2019 · D2 50,000 IU twice weekly · Adults aged 25–85 years with 25(OH)D below 30 ng/mL | 500 mg | 7,143 IU | 1 year | — |
| Effect of 6-Month Vitamin D Supplementation on Plasma Matrix Gla Protein in Older Adults 2019 · Vitamin D3 group · Adults aged 60–80 with low serum 25(OH)D, clinically relevant depressive symptoms, and at least one functional limitation | 500 mg | 1,200 IU | 26 weeks | — |
| Calcium and vitamin D supplementation and bone health in Marine recruits: Effect of season 2019 · Ca + D fortified snack bars · Male and female Marine recruits, mean age 18.9 years, undergoing 12 weeks of initial military training | 2 g | 1,000 IU | 12 weeks | — |
| Vitamin D-A Risk Factor for Bone Fractures in Children: A Population-Based Prospective Case-Control Randomized Cross-Sectional Study 2023 · study group · Children aged 2–17 years with fractures; supplementation was given when serum 25-OH-vitamin D was below 30 ng/mL. | 600 mg | 2,000 IU | 26 weeks | — |
| High-dose cholecalciferol supplementation to obese infertile men is sufficient to reach adequate vitamin D status 2024 · active group · Infertile men, including men with normal weight, overweight, and obesity | 500 mg | 301 g | 150 days | — |
| Effects of postmenopausal hormone replacement therapy with and without vitamin D3 on circulating levels of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D 1998 · Vit D3 group · Postmenopausal women | 500 mg | — | 1 year | — |
| Effects of postmenopausal hormone replacement therapy with and without vitamin D3 on circulating levels of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D 1998 · HRT + Vit D3 group · Postmenopausal women | 500 mg | — | 1 year | — |
| Maternal B-vitamin and vitamin D status before, during, and after pregnancy and the influence of supplementation preconception and during pregnancy: Prespecified secondary analysis of the NiPPeR double-blind randomized controlled trial 2023 · intervention · Women planning pregnancy; generally healthy, recruited before conception | 150 mg | 10 mcg | — | 870 |
| Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis 2010 · Placebo group · Postmenopausal women with osteoporosis and prevalent fractures | 1 g | — | 548 days | 544 |
| Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis 2010 · Teriparatide 20 μg group · Postmenopausal women with osteoporosis and prevalent fractures | 1 g | — | 548 days | 541 |
| Vitamin D Supplementation Improves Fasting Insulin Levels and HDL Cholesterol in Infertile Men 2022 · Vitamin D and calcium group · Infertile men; age not stated | 500 mg | 1,400 IU | 150 days | 151 |
| Delta-like 1 (DLK1) is a possible mediator of vitamin D effects on bone and energy metabolism 2020 · high dose vitamin D3 arm · Adults aged 65 years or older, overweight, ambulatory, with serum 25(OH)D of 10–30 ng/ml | 1 g | 3,750 IU | 1 year | 129 |
| Delta-like 1 (DLK1) is a possible mediator of vitamin D effects on bone and energy metabolism 2020 · low dose vitamin D3 arm · Adults aged 65 years or older, overweight, ambulatory, with serum 25(OH)D of 10–30 ng/ml | 1 g | 600 IU | 1 year | 128 |
| Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis 2007 · PTH group · Postmenopausal women with low bone mineral density and osteoporosis | 500 mg | 400 IU | 1 year | 119 |
| Randomized study on oral administration of calcitriol to prevent symptomatic hypocalcemia after total thyroidectomy 2005 · Group B · Patients after total thyroidectomy | 1.5 g | 2 mcg | — | 111 |
| Randomized study on oral administration of calcitriol to prevent symptomatic hypocalcemia after total thyroidectomy 2005 · Group A · Patients after total thyroidectomy | 1.5 g | 1 mcg | — | 104 |
| Clinical and laboratory safety of one year's use of a combination calcium + vitamin D tablet in ambulatory elderly women with vitamin D insufficiency: results of a multicenter, randomized, double-blind, placebo-controlled study 2005 · calcium + vitamin D group · Ambulatory women older than 65 years with vitamin D insufficiency (25-hydroxyvitamin D level ≤12 ng/mL) | 1 g | — | 1 year | 95 |
| A Combined Nutrition and Exercise Intervention Influences Serum Vitamin B-12 and 25-Hydroxyvitamin D and Bone Turnover of Healthy Chinese Middle-Aged and Older Adults 2020 · intervention group · Chinese men and women aged 50 years or older, apparently healthy and community-dwelling | 1.01 g | 30 mcg | 24 weeks | 80 |
| Acute effects of calcitonin nasal spray on serum C-telopeptide of type 1 collagen (CTx) levels in elderly osteopenic women with increased bone turnover 2004 · Calcitonin group · Women older than 65 with high bone turnover, at high risk of osteoporosis | 500 mg | 200 IU | 26 weeks | 75 |
| Primary hyperparathyroidism and metabolic risk factors, impact of parathyroidectomy and vitamin D supplementation, and results of a randomized double-blind study 2013 · D+ group · Adults with primary hyperparathyroidism after parathyroidectomy | 1 g | 1,600 IU | 1 year | 75 |
| Consumption of a calcium and vitamin D-fortified food product does not affect iron status during initial military training: a randomised, double-blind, placebo-controlled trial 2016 · Ca/vitamin D group · Young adult male and female volunteers enrolled in US Army basic combat training | 2 g | 25 mcg | 9 weeks | 75 |
| Effects of vitamin D supplementation on salivary immune responses during Marine Corps basic training 2019 · Vitamin D3 + calcium group · Male and female US Marine Corps recruits entering basic training; ages and vitamin D status not specified | 2 g | 1,000 IU | 12 weeks | 73 |
| Impact of vitamin D supplementation during lactation on vitamin D status and body composition of mother-infant pairs: a MAVID randomized controlled trial 2014 · 1200 IU/d group · Caucasian lactating mothers who delivered a healthy term infant and intended to breastfeed for 6 months | 200 mg | 800 IU | 26 weeks | 70 |
| Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial 2003 · mid-dose · Postmenopausal Chinese women aged 48–62 years | 500 mg | 125 IU | 1 year | 68 |
| Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial 2003 · high dose · Postmenopausal Chinese women aged 48–62 years | 500 mg | 125 IU | 1 year | 68 |
| Comparison of the effects of ossein-hydroxyapatite complex and calcium carbonate on bone metabolism in women with senile osteoporosis: a randomized, open-label, parallel-group, controlled, prospective study 2011 · calcium carbonate (control group) · Women aged over 65 years with densitometric osteoporosis of the lumbar spine or femoral neck | 1 g | — | 3 years | 65 |
| Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis 2007 · PTH/alendronate combination group · Postmenopausal women with low bone mineral density and osteoporosis | 500 mg | 400 IU | 1 year | 59 |
| Comparison of the effects of ossein-hydroxyapatite complex and calcium carbonate on bone metabolism in women with senile osteoporosis: a randomized, open-label, parallel-group, controlled, prospective study 2011 · OHC (treatment group) · Women aged over 65 years with densitometric osteoporosis of the lumbar spine or femoral neck | 1.66 g | — | 3 years | 55 |
| Bioavailability of calcium: comparison of calcium carbonate and milk and the effect of vitamin D, age, and sex using 24-hour urine calcium as a method 2005 · CaCO(3) + cholecalciferol · Healthy younger women and older women and men; median ages 30 and 66, respectively | 1.2 g | 1,200 IU | 4 weeks | 53 |
| Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate 2008 · ALN add TPTD · Postmenopausal women with osteoporosis previously treated with alendronate | 500 mg | 400 IU | 26 weeks | 52 |
| Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate 2008 · ALN switch TPTD · Postmenopausal women with osteoporosis previously treated with alendronate | 500 mg | 400 IU | 26 weeks | 50 |
| Consumption of vitamin D-fortified yogurt drink increased leptin and ghrelin levels but reduced leptin to ghrelin ratio in type 2 diabetes patients: a single blind randomized controlled trial 2017 · Vitamin D3-fortified doogh (FD) · Adults with type 2 diabetes; age and sex not specified | 340 mg | 1,000 IU | 12 weeks | 50 |
| Once daily calcium (1000 mg) and vitamin D (1000 IU) supplementation during military training prevents increases in biochemical markers of bone resorption but does not affect tibial microarchitecture in Army recruits 2022 · Ca + D fortified food bar · Male and female Army recruits undergoing basic combat training; mean age 21.8 years | 1 g | 1,000 IU | 8 weeks | 50 |
| Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate 2008 · RLX switch TPTD · Postmenopausal women with osteoporosis previously treated with raloxifene | 500 mg | 400 IU | 26 weeks | 49 |
| Effect of oral calcitriol pulse therapy on the lipid, calcium, and glucose homeostasis of hemodialysis-patients: its safety in a combination with oral calcium carbonate 2003 · Calcitriol pulse therapy (crossover) with calcium carbonate · Adults with chronic hemodialysis; age and sex not reported | 4.5 g | — | 26 weeks | 48 |
| Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456] 2004 · Control group · Postmenopausal women aged 45–65 with active rheumatoid arthritis | 500 mg | 400 IU | 2 years | 47 |
| Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate 2008 · RLX add TPTD · Postmenopausal women with osteoporosis previously treated with raloxifene | 500 mg | 400 IU | 26 weeks | 47 |
| Effect of phylloquinone (vitamin K1) supplementation for 12 months on the indices of vitamin K status and bone health in adult patients with Crohn's disease 2014 · 1000 μg vitamin K/d plus calcium and vitamin D3 group (main RCT) · Adults with Crohn's disease, currently in remission | 500 mg | 10 mcg | 1 year | 43 |
| Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456] 2004 · HRT group · Postmenopausal women aged 45–65 with active rheumatoid arthritis | 500 mg | 400 IU | 2 years | 41 |
| The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study 2009 · Group 1 · Postmenopausal women with osteoporosis | 1 g | 400 IU | 1 year | 41 |
| Effect of vitamin D, calcium and multiple micronutrients supplementation on lipid profile in pre-menopausal Bangladeshi garment factory workers with hypovitaminosis D 2014 · VD-Ca group · Young pre-menopausal female garment factory workers with hypovitaminosis D; ages reported as group mean 23.0 years | 600 mg | 400 IU | 1 year | 41 |
| The effect of high-dose vitamin D supplementation on insulin resistance and arterial stiffness in patients with type 2 diabetes 2014 · vitamin D group · Adults aged 30–69 with vitamin D-deficient type 2 diabetes | 200 mg | 2,000 IU | 24 weeks | 40 |
| Changes in biochemical indices of bone metabolism in post-menopausal women following a dietary intervention with fortified dairy products 2009 · dairy intervention group (IG) · Post-menopausal women | 1.2 g | 7.5 mcg | 150 days | 39 |
| Evaluation of weekly risedronate treatment in postmenopausal women with osteoprotegerin 2011 · First group · Postmenopausal women with osteoporosis | 600 mg | 400 IU | 26 weeks | 37 |
| Effect of vitamin D, calcium and multiple micronutrients supplementation on lipid profile in pre-menopausal Bangladeshi garment factory workers with hypovitaminosis D 2014 · MMN-VD-Ca group · Young pre-menopausal female garment factory workers with hypovitaminosis D; ages reported as group mean 22.4 years | 600 mg | 400 IU | 1 year | 37 |
| Consumption of vitamin D-and calcium-fortified soft white cheese lowers the biochemical marker of bone resorption TRAP 5b in postmenopausal women at moderate risk of osteoporosis fracture 2012 · treated · Healthy postmenopausal women aged 56.6 ± 3.9 years with low spontaneous calcium and vitamin D intake | 400 mg | 2.5 mcg | 6 weeks | 36 |
| Role of vitamin D-calcium supplementation on metabolic profile and oxidative stress in gestational diabetes mellitus: A randomized controlled trial 2021 · group B · Women diagnosed with gestational diabetes mellitus at 24–28 weeks of gestation, controlled on a diabetic diet | 500 mg | 250 IU | 6 weeks | 36 |
| Evaluation of weekly risedronate treatment in postmenopausal women with osteoprotegerin 2011 · Second group · Postmenopausal women with osteoporosis | 600 mg | 400 IU | 26 weeks | 34 |
| Clinical Research of the Application of Bone Turnover Markers in Monitoring the Short-Term Therapeutic Efficacy of Vitamin D in Postmenopausal Osteoporotic women in Harbin, China 2020 · low VitD experimental group · Postmenopausal women with osteoporosis and serum 25(OH)D <10 ng/mL | 600 mg | 0.25 mcg | 26 weeks | 34 |
| Role of vitamin D-calcium supplementation on metabolic profile and oxidative stress in gestational diabetes mellitus: A randomized controlled trial 2021 · group A · Women diagnosed with gestational diabetes mellitus at 24–28 weeks of gestation, controlled on a diabetic diet | 1 g | 1,000 IU | 6 weeks | 34 |
| Choline-stabilized orthosilicic acid supplementation as an adjunct to calcium/vitamin D3 stimulates markers of bone formation in osteopenic females: a randomized, placebo-controlled trial 2008 · ch-OSA 3 mg Si · Mostly postmenopausal women, mean age about 60, with osteopenia and otherwise healthy | 1 g | 20 mcg | 1 year | 33 |
| Choline-stabilized orthosilicic acid supplementation as an adjunct to calcium/vitamin D3 stimulates markers of bone formation in osteopenic females: a randomized, placebo-controlled trial 2008 · ch-OSA 6 mg Si · Mostly postmenopausal women, mean age about 60, with osteopenia and otherwise healthy | 1 g | 20 mcg | 1 year | 33 |
| Choline-stabilized orthosilicic acid supplementation as an adjunct to calcium/vitamin D3 stimulates markers of bone formation in osteopenic females: a randomized, placebo-controlled trial 2008 · ch-OSA 12 mg Si · Mostly postmenopausal women, mean age about 60, with osteopenia and otherwise healthy | 1 g | 20 mcg | 1 year | 33 |
| The effects of vitamin D, K and calcium co-supplementation on carotid intima-media thickness and metabolic status in overweight type 2 diabetic patients with CHD 2016 · vitamin D, vitamin K and calcium supplements · Overweight patients with type 2 diabetes and CHD; age and sex not specified | 1 g | 10 mcg | 12 weeks | 33 |
| Between-meal risedronate does not alter bone turnover in nursing home residents 2006 · Risedronate group · Skilled nursing-home residents, mean age 76 years; 46 men and 14 women overall, with hypovitaminosis D common at baseline | 630 mg | 400 IU | 12 weeks | 31 |
| Reduced bone resorption by intake of dietary vitamin D and K from tailor-made Atlantic salmon: A randomized intervention trial 2016 · HD/HK · Postmenopausal women aged 50–65 years | 1 g | 16.3 mcg | 12 weeks | 31 |
| Reduced bone resorption by intake of dietary vitamin D and K from tailor-made Atlantic salmon: A randomized intervention trial 2016 · HD/LK · Postmenopausal women aged 50–65 years | 1 g | 15 mcg | 12 weeks | 31 |
| Effect of adding B-vitamins to vitamin D and calcium supplementation on CpG methylation of epigenetic aging markers 2018 · D + Ca · Adults, mean age 68.4 years; no specific condition stated | 800 mg | — | 1 year | 31 |
| A pilot intervention to increase calcium intake in female collegiate athletes 2004 · treatment group · Female collegiate athletes with regular menstrual cycles; age not reported | 1 g | 400 IU | 16 weeks | 30 |
| Daily intake of vitamin D- or calcium-vitamin D-fortified Persian yogurt drink (doogh) attenuates diabetes-induced oxidative stress: evidence for antioxidative properties of vitamin D 2014 · vitamin D-fortified doogh (DD) · Adults aged 30–50 of both sexes with type 2 diabetes | 300 mg | 1,000 IU | 12 weeks | 30 |
| Daily intake of vitamin D- or calcium-vitamin D-fortified Persian yogurt drink (doogh) attenuates diabetes-induced oxidative stress: evidence for antioxidative properties of vitamin D 2014 · calcium-vitamin D-fortified doogh (CDD) · Adults aged 30–50 of both sexes with type 2 diabetes | 500 mg | 1,000 IU | 12 weeks | 30 |
| Effects of calcium-vitamin D co-supplementation on metabolic profiles in vitamin D insufficient people with type 2 diabetes: a randomised controlled clinical trial 2014 · calcium-vitamin D group · Adults aged over 30 with type 2 diabetes and insufficient 25-hydroxyvitamin D | 1 g | — | 8 weeks | 30 |
| The effects of vitamin D plus calcium supplementation on metabolic profiles, biomarkers of inflammation, oxidative stress and pregnancy outcomes in pregnant women at risk for pre-eclampsia 2016 · vitamin D3 plus calcium · Pregnant women at risk for pre-eclampsia, from 20 to 32 weeks of gestation | 1 g | — | 12 weeks | 30 |
| The Effects of Vitamin D-K-Calcium Co-Supplementation on Endocrine, Inflammation, and Oxidative Stress Biomarkers in Vitamin D-Deficient Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial 2016 · vitamin D-K-calcium co-supplementation group · Vitamin D-deficient women aged 18–40 years with polycystic ovary syndrome | 1 g | 400 IU | 8 weeks | 30 |
| Reduced bone resorption by intake of dietary vitamin D and K from tailor-made Atlantic salmon: A randomized intervention trial 2016 · LD/HK · Postmenopausal women aged 50–65 years | 1 g | 3.86 mcg | 12 weeks | 30 |
| Between-meal risedronate does not alter bone turnover in nursing home residents 2006 · Placebo group · Skilled nursing-home residents, mean age 76 years; 46 men and 14 women overall, with hypovitaminosis D common at baseline | 630 mg | 400 IU | 12 weeks | 29 |
| Consumption of yogurts fortified in vitamin D and calcium reduces serum parathyroid hormone and markers of bone resorption: a double-blind randomized controlled trial in institutionalized elderly women 2013 · vitamin D- and calcium-fortified yogurt (FY) · Institutionalized women, mean age 85.5 years, at high risk for vitamin D deficiency and osteoporotic fracture | 800 mg | 10 mcg | 8 weeks | 29 |
| Effects of calcium-vitamin D co-supplementation on glycaemic control, inflammation and oxidative stress in gestational diabetes: a randomised placebo-controlled trial 2014 · calcium-vitamin D group · Pregnant women aged 18–40 years with gestational diabetes at 24–28 weeks' gestation | 1 g | — | 6 weeks | 28 |
| The Effects of Calcium, Vitamins D and K co-Supplementation on Markers of Insulin Metabolism and Lipid Profiles in Vitamin D-Deficient Women with Polycystic Ovary Syndrome 2017 · calcium, vitamin D and vitamin K group · Women aged 18–40 years with vitamin D deficiency and polycystic ovary syndrome | 1 g | 400 IU | 8 weeks | 28 |
| Plasma parathyroid hormone response to vitamin D3 supplementation among women of reproductive age: A randomized double-blind placebo-control trial 2022 · 600 IU vitamin D3 + 500 mg calcium · Women aged 20–45 years in Malaysia; vitamin D status varied, with most participants below 50 nmol/L at baseline. | 500 mg | 600 IU | 16 weeks | 28 |
| Plasma trimethylamine-N-oxide following supplementation with vitamin D or D plus B vitamins 2017 · vitamin D arm · Participants; age, sex, and health condition not specified | 800 mg | 1,200 IU | 1 year | 27 |
| Effect of calcium and vitamin D supplementation with and without collagen peptides on bone turnover in postmenopausal women with osteopenia 2020 · Group B (control) · Postmenopausal women with osteopenia | 1.25 g | 400 IU | 90 days | 27 |
| Calcium plus vitamin D supplementation influences biomarkers of inflammation and oxidative stress in overweight and vitamin D-deficient women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial 2015 · Group C · Overweight, vitamin D-deficient women aged 18–40 years with PCOS | 1 g | 7,143 IU | 8 weeks | 26 |
| Plasma parathyroid hormone response to vitamin D3 supplementation among women of reproductive age: A randomized double-blind placebo-control trial 2022 · 1200 IU vitamin D3 + 500 mg calcium · Women aged 20–45 years in Malaysia; vitamin D status varied, with most participants below 50 nmol/L at baseline. | 500 mg | 1,200 IU | 16 weeks | 26 |
| Plasma parathyroid hormone response to vitamin D3 supplementation among women of reproductive age: A randomized double-blind placebo-control trial 2022 · 4000 IU vitamin D3 + 500 mg calcium · Women aged 20–45 years in Malaysia; vitamin D status varied, with most participants below 50 nmol/L at baseline. | 500 mg | 4,000 IU | 16 weeks | 26 |
| Risk of calcium oxalate nephrolithiasis after calcium or combined calcium and calcitriol supplementation in postmenopausal women 2000 · calcium carbonate plus calcitriol · Thai postmenopausal women with osteoporosis, more than 10 years postmenopausal | 750 mg | 0.5 mcg | 90 days | 25 |
| A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis 2010 · Treatment group · Patients with multiple sclerosis; age and sex not specified | 1.2 g | 40,000 IU | 52 weeks | 25 |
| Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis 2011 · treated patients · Patients with multiple sclerosis; age and sex ranges not reported | 1.2 g | — | 1 year | 25 |
| Clinical Research of the Application of Bone Turnover Markers in Monitoring the Short-Term Therapeutic Efficacy of Vitamin D in Postmenopausal Osteoporotic women in Harbin, China 2020 · high VitD experimental group · Postmenopausal women with osteoporosis and serum 25(OH)D ≥10 ng/mL | 600 mg | 0.25 mcg | 26 weeks | 25 |
| The effect of daily intake of vitamin D-fortified yogurt drink, with and without added calcium, on serum adiponectin and sirtuins 1 and 6 in adult subjects with type 2 diabetes 2021 · Ca+D-yogurt drink (CDY) · Adults aged 30–60 years with confirmed type 2 diabetes | 500 mg | 1,000 IU | 12 weeks | 25 |
| Effect of calcium-vitamin D supplementation on metabolic profiles in pregnant women at risk for pre-eclampsia: a randomized placebo-controlled trial 2012 · calcium-vitamin D supplements · Pregnant women aged 18–35 in the third trimester, primigravida, with singleton pregnancies and at risk for pre-eclampsia | 500 mg | 200 IU | 9 weeks | 24 |
| Effect of calcium and vitamin D supplementation with and without collagen peptides on bone turnover in postmenopausal women with osteopenia 2020 · Group A · Postmenopausal women with osteopenia | 3.6 g | 400 IU | 90 days | 24 |
| Alfacalcidol (alpha D3) and calcium in osteoporosis 1994 · treatment group · Postmenopausal women with osteoporosis; mean age 67 years | 1 g | 0.5 mcg | 3 years | 24 |
| Acute effects of calcitonin nasal spray on serum C-telopeptide of type 1 collagen (CTx) levels in elderly osteopenic women with increased bone turnover 2004 · Calcium and vitamin D control group · Women older than 65 with high bone turnover, at high risk of osteoporosis | 500 mg | 200 IU | 26 weeks | 23 |
| Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis 2004 · No-alendronate group (controls) · HIV-infected men and women on stable HAART with osteopenia or osteoporosis | 1 g | 500 IU | 52 weeks | 23 |
| Effects of vitamin D and calcium supplementation on markers of apoptosis in normal colon mucosa: a randomized, double-blind, placebo-controlled clinical trial 2009 · 2.0 g elemental calcium plus 800 IU vitamin D3 · Adults aged 30–75 in generally good health with at least one pathology-confirmed sporadic colon or rectal adenoma in the previous 36 months | 2 g | 800 IU | 26 weeks | 23 |
| Effects of vitamin d and calcium on proliferation and differentiation in normal colon mucosa: a randomized clinical trial 2009 · calcium plus vitamin D supplementation group · Adults aged 30–75 in general good health with a history of at least one pathology-confirmed colorectal adenoma within the past 36 months | 2 g | 800 IU | 26 weeks | 23 |
| Effects of calcium and vitamin D on MLH1 and MSH2 expression in rectal mucosa of sporadic colorectal adenoma patients 2010 · calcium plus vitamin D3 supplementation group · Adults aged 30–75 with a history of at least one adenomatous colonic or rectal polyp within the past 36 months | 2 g | 800 IU | 26 weeks | 23 |
| A randomized clinical trial of the effects of supplemental calcium and vitamin D3 on markers of their metabolism in normal mucosa of colorectal adenoma patients 2011 · calcium plus vitamin D3 group · Adults aged 30–75 with a history of at least one pathology-confirmed adenomatous colorectal polyp in the preceding 36 months | 2 g | 800 IU | 180 days | 23 |
| Effects of supplemental vitamin D and calcium on biomarkers of inflammation in colorectal adenoma patients: a randomized, controlled clinical trial 2011 · 2.0 g elemental calcium plus 800 IU vitamin D3 group · Adults aged 30–75 with a history of sporadic colorectal adenoma | 2 g | 800 IU | 26 weeks | 23 |
| A randomized clinical trial of the effects of supplemental calcium and vitamin D3 on the APC/β-catenin pathway in the normal mucosa of colorectal adenoma patients 2012 · 2.0 g elemental calcium plus 800 IU vitamin D3 supplementation · Adults aged 30–75 with a history of at least one pathology-confirmed adenomatous colorectal polyp within the past 36 months | 2 g | 800 IU | 26 weeks | 23 |
| Effects of calcium and vitamin D3 on transforming growth factors in rectal mucosa of sporadic colorectal adenoma patients: a randomized controlled trial 2015 · calcium plus vitamin D3 group · Adults aged 30–75 with a history of at least one adenomatous colorectal polyp within the past 36 months; both sexes | 2 g | 800 IU | 26 weeks | 23 |
| Nutritional approach for inhibiting bone resorption in institutionalized elderly women with vitamin D insufficiency and high prevalence of fracture 2011 · Soft plain cheese consumption period · Institutionalized women aged 65 years or older with vitamin D insufficiency and low calcium intake | 302 mg | 2.5 mcg | 6 weeks | 21 |
| The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study 2009 · Group 2 (control group) · Postmenopausal women with osteoporosis | 1 g | 400 IU | 1 year | 20 |
| Calcium and vitamin-D supplementation on bone structural properties in peripubertal female identical twins: a randomised controlled trial 2011 · calcium-supplemented group · Peripubertal girls aged 9 to 13 years | 800 mg | 400 IU | 26 weeks | 20 |
| Potassium Citrate Supplementation Decreases the Biochemical Markers of Bone Loss in a Group of Osteopenic Women: The Results of a Randomized, Double-Blind, Placebo-Controlled Pilot Study 2018 · K citrate group · Postmenopausal women with osteopenia, more than 5 years post-menopause | 500 mg | 400 IU | 26 weeks | 20 |
| Potassium Citrate Supplementation Decreases the Biochemical Markers of Bone Loss in a Group of Osteopenic Women: The Results of a Randomized, Double-Blind, Placebo-Controlled Pilot Study 2018 · Placebo group with background supplements · Postmenopausal women with osteopenia, more than 5 years post-menopause | 500 mg | 400 IU | 26 weeks | 20 |
| Bioavailability of calcium supplements and the effect of Vitamin D: comparisons between milk, calcium carbonate, and calcium carbonate plus vitamin D 1996 · three tablets containing 1000 mg CaCO3 plus 5 micrograms (200 IU) vitamin D/d · Healthy women aged 28–59 years | 1 g | 5 mcg | 3 days | 20 |
| Impact of Omega-3 and Vitamin D Supplementation on Bone Turnover Markers in Children with Leukemia: Follow-Up During and After Supplementation 2025 · ω-3VDCa group · Children aged 5–17 years with acute lymphoblastic leukemia in the maintenance phase | 1 g | 4,000 IU | 6 weeks | 19 |
| Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis 2004 · Alendronate-treatment group · HIV-infected men and women on stable HAART with osteopenia or osteoporosis | 1 g | 500 IU | 52 weeks | 18 |
| Effects of supplemental vitamin D and calcium on markers of proliferation, differentiation, and apoptosis in the normal colorectal mucosa of colorectal adenoma patients 2018 · Calcium + Vitamin D (4-arm randomization) · Adults aged 45–75 with a removed histologically verified colorectal adenoma; men and women | 1.2 g | 1,000 IU | 1 year | 17 |
| Temporal Change in Biomarkers of Bone Turnover Following Late Evening Ingestion of a Calcium-Fortified, Milk-Based Protein Matrix in Postmenopausal Women with Osteopenia 2019 · milk-based protein matrix (MBPM) · Postmenopausal women aged 50–70 with osteopenia | 875 mg | — | 1 day | 16 |
| Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women 2008 · calcium and vitamin D group · Postmenopausal women with osteoporosis | 1 g | — | 90 days | 13 |
| Effect of vitamin D and calcium supplementation on bone turnover in institutionalized adults with Down's Syndrome 2006 · supplementation group · Adults with Down's syndrome living in an institution | 1 g | 800 IU | 1 year | 12 |
| [Treatment of postmenopausal osteoporosis with 1-alpha(OH)D3] 1995 · 1-alpha(OH) vitamin D3 group · Postmenopausal women with osteoporosis | 500 mg | 0.5 mcg | 26 weeks | 12 |
| Calcium plus vitamin D alters preneoplastic features of colorectal adenomas and rectal mucosa 2006 · calcium plus vitamin D treatment group · Adults with adenomatous polyps; age and sex not stated | 4.5 g | 400 IU | 26 weeks | 11 |
| Systemic vitamin D supplementation and local bone formation after maxillary sinus augmentation - a randomized, double-blind, placebo-controlled clinical investigation 2016 · vitamin D3 + calcium group · Adults undergoing maxillary sinus augmentation; age and sex not stated | 600 mg | 5,000 IU | 213 days | 10 |
| SECONDARY HYPERPARATHYROIDISM AFTER BARIATRIC SURGERY: TREATMENT IS WITH CALCIUM CARBONATE OR CALCIUM CITRATE? 2015 · Calcium citrate group (Group 1 in Methods) · Adults who underwent Roux-en-Y gastric bypass and had mainly abnormal alkaline phosphatase, vitamin D and PTH levels; ages 25–55 | 1.2 g | 800 IU | 60 days | 10 |
| SECONDARY HYPERPARATHYROIDISM AFTER BARIATRIC SURGERY: TREATMENT IS WITH CALCIUM CARBONATE OR CALCIUM CITRATE? 2015 · Calcium carbonate group (Group 2 in Methods) · Adults who underwent Roux-en-Y gastric bypass and had mainly abnormal alkaline phosphatase, vitamin D and PTH levels; ages 25–68 | 1.2 g | 800 IU | 60 days | 10 |
| Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD 1994 · intravenous group · Hemodialysis patients with end-stage renal disease and severe hyperparathyroidism; age and sex not reported | 2.5 g | — | 36 weeks | 10 |
| Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD 1994 · pulse oral group · Hemodialysis patients with end-stage renal disease and severe hyperparathyroidism; age and sex not reported | 2.5 g | — | 36 weeks | 9 |
| A randomized trial comparing 2.5 mEq/L calcium dialysate and calcitriol to 3.5 mEq/L calcium dialysate in patients on peritoneal dialysis 1993 · Study group: 2.5 mEq/L calcium dialysate with oral calcitriol · Patients on peritoneal dialysis | 900 mg | 0.25 mcg | 8 weeks | 9 |
| Tibial bone responses to 6-month calcium and vitamin D supplementation in young male jockeys: A randomised controlled trial 2015 · Supplemented group · Apprentice male jockeys, mean age 20.2 ± 3.2 years, engaged in caloric restriction and high volumes of physical activity | 800 mg | 400 IU | 26 weeks | 8 |
| The effect of calcium and vitamin D supplementation on bone health of male Jockeys 2017 · calcium and vitamin D group · Apprentice male jockeys; mean age 20.18 ± 3.23 years | 800 mg | 400 IU | 26 weeks | 8 |
| Influence of daily calcium and vitamin D supplementation on parathyroid hormone secretion 2001 · Two doses of Orocal D3 at a 6-hour interval · Healthy male volunteers; age not stated | 1 g | 800 IU | 1 day | — |
| Influence of daily calcium and vitamin D supplementation on parathyroid hormone secretion 2001 · One morning dose of Cacit vitamin D3 · Healthy male volunteers; age not stated | 1 g | 880 IU | 1 day | — |
| Alendronate prevents further bone loss in renal transplant recipients 2001 · Group A · Adults aged 44.2 ± 11.6 years with a kidney transplant at least 6 months earlier | 500 mg | 0.5 mcg | 1 year | — |
| Alendronate prevents further bone loss in renal transplant recipients 2001 · Group B · Adults aged 44.2 ± 11.6 years with a kidney transplant at least 6 months earlier | 500 mg | 0.5 mcg | 1 year | — |
| Influence of daily regimen calcium and vitamin D supplementation on parathyroid hormone secretion 2002 · Two doses of Orocal D3 · Healthy volunteers; age and sex not specified | 1 g | 800 IU | 1 day | — |
| Influence of daily regimen calcium and vitamin D supplementation on parathyroid hormone secretion 2002 · Single morning dose of Cacit D3 · Healthy volunteers; age and sex not specified | 1 g | 880 IU | 1 day | — |
| Administration of a supplement containing both calcium and vitamin D is more effective than calcium alone to reduce secondary hyperparathyroidism in postmenopausal women with low 25(OH)vitamin D circulating levels 2002 · calcium-vitamin D (CaD) group · postmenopausal women with serum 25(OH)vitamin D levels below 18 ng/mL | 500 mg | 200 IU | 90 days | — |
| Comparisons of oral calcium, high dose vitamin D and a combination of these in the treatment of nutritional rickets in children 2002 · Vitamin D plus calcium group · Infants aged 6–30 months with nutritional rickets | 3 g | — | 4 weeks | — |
| Comparison of the effects of calcium loading with calcium citrate or calcium carbonate on bone turnover in postmenopausal women 2004 · calcium citrate · Older postmenopausal women | 1 g | 900 IU | 12 weeks | — |
| Comparison of the effects of calcium loading with calcium citrate or calcium carbonate on bone turnover in postmenopausal women 2004 · calcium carbonate · Older postmenopausal women | 1 g | 900 IU | 12 weeks | — |
| Mineral water fortified with folic acid, vitamins B6, B12, D and calcium improves folate status and decreases plasma homocysteine concentration in men and women 2004 · Fortified mineral water · Free-living men and women without folate deficiency or elevated homocysteine | 563 mg | 0.6 mcg | 8 weeks | — |
| Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk 2004 · placebo · Postmenopausal women with osteoporosis | 500 mg | — | 3 years | — |
| Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk 2004 · raloxifene 60 mg/day · Postmenopausal women with osteoporosis | 500 mg | — | 3 years | — |
| Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk 2004 · raloxifene 120 mg/day · Postmenopausal women with osteoporosis | 500 mg | — | 3 years | — |
| Changes in bone turnover markers after calcium-enriched milk supplementation in healthy postmenopausal women: a randomized, double-blind, prospective clinical trial 2005 · group A · Postmenopausal women aged 49–71 years; healthy | 1.2 g | 5.7 mcg | 26 weeks | — |
| Changes in bone turnover markers after calcium-enriched milk supplementation in healthy postmenopausal women: a randomized, double-blind, prospective clinical trial 2005 · group B · Postmenopausal women aged 49–71 years; healthy | 900 mg | 5.7 mcg | 26 weeks | — |
| Consumption of a high calcium mineral water lowers biochemical indices of bone remodeling in postmenopausal women with low calcium intake 2005 · High-calcium mineral water plus vitamin D · Postmenopausal women with dietary calcium intake below 700 mg/day; mean age 70.1 years | 596 mg | 400 IU | 26 weeks | — |
| Dietary acid-base balance, bone resorption, and calcium excretion 2006 · Cereal (acidogenic) diet group · Healthy older men and women | 600 mg | 400 IU | 60 days | — |
| Dietary acid-base balance, bone resorption, and calcium excretion 2006 · Fruit and vegetable (alkalinogenic) diet group · Healthy older men and women | 600 mg | 400 IU | 60 days | — |
| Effect of calcium, vitamins K1 and D3 on bone in galactosemia 2006 · calcium, vitamins K1 and D3 supplementation · Children aged 3–17 years with classical galactosemia | 750 mg | 10 mcg | 2 years | — |
| The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults 2007 · calcium and vitamin D supplementation · Caucasian adults aged 65 years or older without diabetes; baseline fasting glucose was normal or impaired | 500 mg | 700 IU | 3 years | — |
| Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide 2007 · Placebo · Adults with osteoporosis or low bone mass: postmenopausal women and men | 1 g | — | 1 year | — |
| Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide 2007 · TPTD 20 microg/d · Adults with osteoporosis or low bone mass: postmenopausal women and men | 1 g | — | 1 year | — |
| Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide 2007 · TPTD 40 microg/d · Adults with osteoporosis or low bone mass: postmenopausal women and men | 1 g | — | 1 year | — |
| Biochemical short-term changes produced by hormonal replacement therapy 1991 · calcium · White postmenopausal women, 6 months to 6 years after menopause | 1.7 g | 400 IU | 60 days | — |
| Biochemical short-term changes produced by hormonal replacement therapy 1991 · cyclic estrogen-progestin plus calcium · White postmenopausal women, 6 months to 6 years after menopause | 1.7 g | 400 IU | 60 days | — |
| Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss 2008 · Placebo group · Postmenopausal Korean women aged 50–65 with moderate bone loss | 600 mg | 400 IU | 12 weeks | — |
| Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss 2008 · Alendronate group · Postmenopausal Korean women aged 50–65 with moderate bone loss | 600 mg | 400 IU | 12 weeks | — |
| Treatment with potassium bicarbonate lowers calcium excretion and bone resorption in older men and women 2009 · placebo · Men and women aged 50 and older; described as healthy older adults | 600 mg | 525 IU | 90 days | — |
| Treatment with potassium bicarbonate lowers calcium excretion and bone resorption in older men and women 2009 · potassium bicarbonate group · Men and women aged 50 and older; described as healthy older adults | 600 mg | 525 IU | 90 days | — |
| Treatment with potassium bicarbonate lowers calcium excretion and bone resorption in older men and women 2009 · sodium bicarbonate group · Men and women aged 50 and older; described as healthy older adults | 600 mg | 525 IU | 90 days | — |
| Treatment with potassium bicarbonate lowers calcium excretion and bone resorption in older men and women 2009 · potassium chloride group · Men and women aged 50 and older; described as healthy older adults | 600 mg | 525 IU | 90 days | — |
| The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD 2009 · calcium-vitamin D(3) fixed combination · Elderly white women; the analysis focused on participants with moderate chronic kidney disease | 1.2 g | 800 IU | 26 weeks | — |
| The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD 2009 · calcium plus vitamin D(3) separate combination · Elderly white women; the analysis focused on participants with moderate chronic kidney disease | 1.2 g | 800 IU | 26 weeks | — |
| Effects of supplemental vitamin D and calcium on oxidative DNA damage marker in normal colorectal mucosa: a randomized clinical trial 2010 · calcium plus vitamin D supplementation group · Adults aged 30–75 with a history of at least one adenomatous colorectal polyp | 2 g | 800 IU | 26 weeks | — |
| Suppression of C-terminal telopeptide in hypovitaminosis D requires calcium as well as vitamin D 2010 · group 1 · postmenopausal volunteers with initial serum 25OHD below 60 nmol/L | 1 g | 1,000 IU | 8 weeks | — |
| Suppression of C-terminal telopeptide in hypovitaminosis D requires calcium as well as vitamin D 2010 · group 2 · postmenopausal volunteers with initial serum 25OHD below 60 nmol/L | 1 g | 1,000 IU | 8 weeks | — |
| The relative influence of calcium intake and vitamin D status on serum parathyroid hormone and bone turnover biomarkers in a double-blind, placebo-controlled parallel group, longitudinal factorial design 2010 · vitamin D3 and calcium · Healthy men and women aged 20–80 years | 1.2 g | 100 mcg | 90 days | — |
| Vitamin D supplementation and bone mass accrual in underprivileged adolescent Indian girls 2010 · Ergocalciferol intervention group · Post-menarcheal underprivileged girls aged 14–15 years in Pune, India | 250 mg | — | — | — |
| Daily consumption of vitamin D- or vitamin D + calcium-fortified yogurt drink improved glycemic control in patients with type 2 diabetes: a randomized clinical trial 2011 · vitamin D-fortified yogurt drink (DY) · people with type 2 diabetes; age and sex not stated | 300 mg | 1,000 IU | 12 weeks | — |
| Daily consumption of vitamin D- or vitamin D + calcium-fortified yogurt drink improved glycemic control in patients with type 2 diabetes: a randomized clinical trial 2011 · vitamin D + calcium-fortified yogurt drink (DCY) · people with type 2 diabetes; age and sex not stated | 500 mg | 1,000 IU | 12 weeks | — |
| Intravenous ibandronate acutely reduces bone hyperresorption in chronic critical illness 2012 · ibandronate group · Postmenopausal women with chronic critical illness | 1.25 g | 0.25 mcg | 11 days | — |
| Intravenous ibandronate acutely reduces bone hyperresorption in chronic critical illness 2012 · placebo group · Postmenopausal women with chronic critical illness | 1.25 g | 0.25 mcg | 11 days | — |
| Inflammatory cytokine responses to progressive resistance training and supplementation with fortified milk in men aged 50+ years: an 18-month randomized controlled trial 2011 · PRT + fortified milk supplement · Healthy men aged 50–79 years | 1 g | 800 IU | 548 days | — |
| Inflammatory cytokine responses to progressive resistance training and supplementation with fortified milk in men aged 50+ years: an 18-month randomized controlled trial 2011 · Fortified milk supplement · Healthy men aged 50–79 years | 1 g | 800 IU | 548 days | — |
| [Changes of serum lipids after soy isoflavone and calcium supplementation in postmenopausal Chinese women with different ER-beta genotypes] 2011 · group II · Postmenopausal Chinese women with normal serum lipids and bone loss or osteoporosis | 440 mg | 100 IU | 1 year | — |
| Improvement of vitamin D status via daily intake of fortified yogurt drink either with or without extra calcium ameliorates systemic inflammatory biomarkers, including adipokines, in the subjects with type 2 diabetes 2012 · vitamin D-fortified doogh (DD) · Adults aged 30–60 of both sexes with type 2 diabetes | 300 mg | 1,000 IU | 12 weeks | — |
| Improvement of vitamin D status via daily intake of fortified yogurt drink either with or without extra calcium ameliorates systemic inflammatory biomarkers, including adipokines, in the subjects with type 2 diabetes 2012 · calcium + vitamin D3-fortified doogh (CDD) · Adults aged 30–60 of both sexes with type 2 diabetes | 500 mg | 1,000 IU | 12 weeks | — |
| Prevention of bone loss in children receiving long-term glucocorticoids with calcium and alfacalcidol or menatetrenone 2012 · alfacalcidol group · Children receiving long-term glucocorticoids | 400 mg | — | 1 year | — |
| Management of nutritional rickets in Indian children: a randomized controlled trial 2013 · combination therapy · Children aged 6 months to 5 years with nutritional rickets | 75 mg/kg | — | 12 weeks | — |
| One year B and D vitamins supplementation improves metabolic bone markers 2013 · group B · Healthy adults older than 54 years | 456 mg | 1,200 IU | 1 year | — |
| Enhanced effect of zinc and calcium supplementation on bone status in growth hormone-deficient children treated with growth hormone: a pilot randomized controlled trial 2013 · Group A · Prepubertal children with growth hormone deficiency, mean age 8.7 ± 2.8 years; 18 boys across the study | 500 mg | — | 1 year | — |
| Regular consumption of both vitamin D- and calcium- and vitamin D-fortified yogurt drink is equally accompanied by lowered blood lipoprotein (a) and elevated apoprotein A1 in subjects with type 2 diabetes: a randomized clinical trial 2013 · vitamin D-fortified doogh (DD) · Men and women aged 30–60 years with type 2 diabetes | 300 mg | 1,000 IU | 12 weeks | — |
| Regular consumption of both vitamin D- and calcium- and vitamin D-fortified yogurt drink is equally accompanied by lowered blood lipoprotein (a) and elevated apoprotein A1 in subjects with type 2 diabetes: a randomized clinical trial 2013 · calcium- and vitamin D-fortified doogh (CDD) · Men and women aged 30–60 years with type 2 diabetes | 500 mg | 1,000 IU | 12 weeks | — |
| Calcium and vitamin d supplementation in postmenopausal women 2013 · vitamin D3 and calcium · healthy postmenopausal white women | 1.2 g | 100 mcg | 26 weeks | — |
| Multinutrient-fortified juices improve vitamin D and vitamin E status in children: a randomized controlled trial 2014 · CaDEA · Children aged approximately 8 years | 700 mg | 200 IU | 12 weeks | — |
| Calcium and vitamin D for osteoprotection in children with new-onset nephrotic syndrome treated with steroids: a prospective, randomized, controlled, interventional study 2014 · intervention group (IG) · Steroid-naïve pre-pubertal children with new-onset nephrotic syndrome treated with glucocorticoids; boys and girls | 500 mg | 1,000 IU | 12 weeks | — |
| Effect of supplemental vitamin D and calcium on serum sclerostin levels 2014 · vitamin D and calcium group · Men and women aged 65 years and older, described as healthy | 500 mg | — | 2 years | — |
| Calcium and vitamin D supplementation maintains parathyroid hormone and improves bone density during initial military training: a randomized, double-blind, placebo controlled trial 2014 · Ca+Vit D · Men and women undergoing Army initial military training (basic combat training); ages and health conditions not specified | 2 g | 1,000 IU | 9 weeks | — |
| Calcium-vitamin D cosupplementation influences circulating inflammatory biomarkers and adipocytokines in vitamin D-insufficient diabetics: a randomized controlled clinical trial 2014 · joint calcium-vitamin D group · Adults with vitamin D insufficiency and type 2 diabetes; age and sex range not stated | 1 g | 7,143 IU | 8 weeks | — |
| Calcium supplementation increases blood creatinine concentration in a randomized controlled trial 2014 · Calcium plus vitamin D · Adults aged 45–75 in generally good health with a previously removed large bowel adenoma; predominantly male | 1.2 g | 1,000 IU | 5 years | — |
| Vitamin D, osteoprotegerin/receptor activator of nuclear factor-kappaB ligand (OPG/RANKL) and inflammation with alendronate treatment in HIV-infected patients with reduced bone mineral density 2016 · Alendronate (ALN) arm · HIV-infected men and women aged 25 years or older with low bone mineral density | 1 g | — | 48 weeks | — |
| Vitamin D, osteoprotegerin/receptor activator of nuclear factor-kappaB ligand (OPG/RANKL) and inflammation with alendronate treatment in HIV-infected patients with reduced bone mineral density 2016 · Placebo arm · HIV-infected men and women aged 25 years or older with low bone mineral density | 1 g | — | 48 weeks | — |
| A Vitamin D-Calcium-Fortified Yogurt Drink Decreased Serum PTH but did not Affect Osteocalcin in Subjects with Type 2 Diabetes 2015 · Group 3 (CDD) · Women and men aged 30–50 years with type 2 diabetes | 500 mg | 1,000 IU | 12 weeks | — |
| Effects of supplemental calcium and vitamin D on the APC/β-catenin pathway in the normal colorectal mucosa of colorectal adenoma patients 2017 · 1,200 mg/day elemental calcium plus 1,000 IU/day vitamin D3 supplementation · Adults aged 45–75 with a history of colorectal adenomas | 1.2 g | 1,000 IU | 1 year | — |
| One-carbon metabolites and telomere length in a prospective and randomized study of B- and/or D-vitamin supplementation 2017 · group B · Adults older than 54 years; no specific condition stated | 456 mg | 1,200 IU | 1 year | — |
| Effects of Calcium, Vitamin D, and Hormone Therapy on Cardiovascular Disease Risk Factors in the Women's Health Initiative: A Randomized Controlled Trial 2017 · Calcium + vitamin D alone · Postmenopausal women aged 50–79 in the WHI hormone therapy trials | 1 g | 400 IU | 5 years | — |
| Effects of Calcium, Vitamin D, and Hormone Therapy on Cardiovascular Disease Risk Factors in the Women's Health Initiative: A Randomized Controlled Trial 2017 · Calcium + vitamin D plus hormone therapy · Postmenopausal women aged 50–79 in the WHI hormone therapy trials | 1 g | 400 IU | 5 years | — |
| Effects of Vitamin D Supplementation on Semen Quality, Reproductive Hormones, and Live Birth Rate: A Randomized Clinical Trial 2018 · active group · Infertile men with serum 25-hydroxyvitamin-D levels ≤50 nmol/L | 500 mg | 1,400 IU | 150 days | — |
| Safety of calcium and vitamin D supplements, a randomized controlled trial 2018 · CaCO3 1200 mg/day with 10 000 IU vitamin D3/day · Healthy, white postmenopausal women | 1.2 g | 10,000 IU | 1 year | — |
| Safety of calcium and vitamin D supplements, a randomized controlled trial 2018 · CaCO3 1200 mg/day with 600 IU vitamin D3/day · Healthy, white postmenopausal women | 1.2 g | 600 IU | 1 year | — |
| Effects of vitamin D and calcium on expression of MSH2 and transforming growth factors in normal-appearing colorectal mucosa of sporadic colorectal adenoma patients: A randomized clinical trial 2019 · vitamin D3 plus calcium group · People with sporadic colorectal adenomas; age and sex not specified | 1.2 g | 1,000 IU | 1 year | — |
| Effects of supplemental calcium and vitamin D on tight-junction proteins and mucin-12 expression in the normal rectal mucosa of colorectal adenoma patients 2019 · calcium plus vitamin D supplementation · Adults aged 45–75 with a removed colorectal adenoma and no remaining polyps after colonoscopy; patients at increased risk for colorectal neoplasms | 1.2 g | 1,000 IU | 1 year | — |
| Inflammation Modulation by Vitamin D and Calcium in the Morphologically Normal Colorectal Mucosa of Patients with Colorectal Adenoma in a Clinical Trial 2021 · calcium plus vitamin D group · Adults aged 45–75 with a histologically verified colorectal adenoma | 1.2 g | 1,000 IU | 1 year | — |
| Vitamin K2 (menaquinone-7) increases plasma adiponectin but does not affect insulin sensitivity in postmenopausal women: a randomized controlled trial 2021 · MK-7 group · Postmenopausal women; the abstract describes them as healthy | 800 mg | 38 mcg | 1 year | — |
| Effect of Vitamin D and/or Calcium Supplementation on Pancreatic β-Cell Function in Subjects with Prediabetes: A Randomized, Controlled Trial 2023 · vitamin D plus calcium group · Chinese adults with prediabetes; the reported disposition-index result was for vitamin D-insufficient individuals | 500 mg | 1,600 IU | 24 weeks | — |
| Elevated PTH levels in hypovitaminosis D are more rapidly suppressed by the administration of 1,25-dihydroxy-vitamin D3 than by vitamin D3 1998 · cholecalciferol group · Inpatients with hypovitaminosis D and secondary hyperparathyroidism | 1 g | 800 IU | 26 weeks | — |
| Elevated PTH levels in hypovitaminosis D are more rapidly suppressed by the administration of 1,25-dihydroxy-vitamin D3 than by vitamin D3 1998 · calcitriol group · Inpatients with hypovitaminosis D and secondary hyperparathyroidism | 500 mg | — | 26 weeks | — |
| Low dose estrogen and calcium have an additive effect on bone resorption in older women 1999 · Calcium plus vitamin D (Ca+D) · Healthy women over 70 years of age | 1.5 g | 800 IU | 12 weeks | — |
| Low dose estrogen and calcium have an additive effect on bone resorption in older women 1999 · Combination Ca+D and E2 · Healthy women over 70 years of age | 1.5 g | 800 IU | 12 weeks | — |
| Safety and tolerability of 6-month supplementation with a vitamin D, calcium and leucine-enriched whey protein medical nutrition drink in sarcopenic older adults 2020 · One-serving WP-MND group during the open-label extension · Adults aged 65 years or older with sarcopenia who continued from the RCT | 500 mg | 800 IU | 13 weeks | 133 |
| Effect of adding B-vitamins to vitamin D and calcium supplementation on CpG methylation of epigenetic aging markers 2018 · D + Ca + B · Adults, mean age 68.4 years; no specific condition stated | 800 mg | — | 1 year | 32 |
| Reduced bone resorption by intake of dietary vitamin D and K from tailor-made Atlantic salmon: A randomized intervention trial 2016 · Tablets · Postmenopausal women aged 50–65 years | 2 g | — | 12 weeks | 30 |
| A Trial on The Effects of Magnesium-Zinc-Calcium-Vitamin D Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome 2017 · Magnesium-zinc-calcium-vitamin D co-supplementation · Women with polycystic ovary syndrome (PCOS) | 800 mg | 400 IU | 12 weeks | 30 |
| The effects of magnesium-zinc-calcium-vitamin D co-supplementation on biomarkers of inflammation, oxidative stress and pregnancy outcomes in gestational diabetes 2019 · Magnesium-zinc-calcium-vitamin D group · Women aged 18–40 with gestational diabetes mellitus, at 24–28 weeks’ gestation at diagnosis | 800 mg | 400 IU | 6 weeks | 30 |
| Plasma trimethylamine-N-oxide following supplementation with vitamin D or D plus B vitamins 2017 · vitamin D + B arm · Participants; age, sex, and health condition not specified | 800 mg | 1,200 IU | 1 year | 25 |
| Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover 2004 · 0.15 mg daily sCT · Healthy postmenopausal women aged 55–85 years | 1 g | 400 IU | 90 days | — |
| Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover 2004 · 0.4 mg daily sCT · Healthy postmenopausal women aged 55–85 years | 1 g | 400 IU | 90 days | — |
| Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover 2004 · 1.0 mg daily sCT · Healthy postmenopausal women aged 55–85 years | 1 g | 400 IU | 90 days | — |
| Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover 2004 · 2.5 mg daily sCT · Healthy postmenopausal women aged 55–85 years | 1 g | 400 IU | 90 days | — |
| Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover 2004 · 1.0 mg intermittent sCT (every other day) · Healthy postmenopausal women aged 55–85 years | 1 g | 400 IU | 90 days | — |
| One year B and D vitamins supplementation improves metabolic bone markers 2013 · group A · Healthy adults older than 54 years | 456 mg | 1,200 IU | 1 year | — |
| Differential effects of calcium- and vitamin D-fortified milk with FOS-inulin compared to regular milk, on bone biomarkers in Chinese pre- and postmenopausal women 2016 · Intervention (Int), premenopausal women · Premenopausal women, mean age 41 years; no specific condition stated | 1 g | 15 mcg | 12 weeks | — |
| Differential effects of calcium- and vitamin D-fortified milk with FOS-inulin compared to regular milk, on bone biomarkers in Chinese pre- and postmenopausal women 2016 · Intervention (Int), postmenopausal women · Postmenopausal women, mean age 59 years; no specific condition stated | 1.2 g | 15 mcg | 12 weeks | — |
| One-carbon metabolites and telomere length in a prospective and randomized study of B- and/or D-vitamin supplementation 2017 · group A · Adults older than 54 years; no specific condition stated | 456 mg | 1,200 IU | 1 year | — |
| A Simplified Regimen Compared with WHO Guidelines Decreases Antenatal Calcium Supplement Intake for Prevention of Preeclampsia in a Cluster-Randomized Noninferiority Trial in Rural Kenya 2017 · standard regimen · Pregnant women enrolled between 16 and 30 weeks of gestation | 1.5 g | 200 IU | 8 weeks | — |
| A Simplified Regimen Compared with WHO Guidelines Decreases Antenatal Calcium Supplement Intake for Prevention of Preeclampsia in a Cluster-Randomized Noninferiority Trial in Rural Kenya 2017 · low-dose regimen · Pregnant women enrolled between 16 and 30 weeks of gestation | 1 g | 200 IU | 8 weeks | — |
| Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial 2016 · placebo · Japanese adults aged 20–74 with rheumatoid arthritis on methotrexate | 600 mg | 400 IU | 1 year | 88 |
| Effect of a single-dose denosumab on mineral homeostasis in infertile men: insights from a pilot intervention study and a randomized controlled trial 2025 · Randomized trial, placebo group · Infertile men; mean age approximately 34 years | 400 mg | 25 mcg | 160 days | 49 |
| Effects of a Multispecies Probiotic Supplement on Bone Health in Osteopenic Postmenopausal Women: A Randomized, Double-blind, Controlled Trial 2017 · placebo group · Postmenopausal women aged 50–72 years with osteopenia | 500 mg | 200 IU | 26 weeks | 25 |
| Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial 2007 · Placebo group · Postmenopausal women with osteoporosis and low bone mineral density at the hip or lumbar spine | 700 mg | — | 548 days | — |
| Genetic variants in CYP2R1, CYP24A1, and VDR modify the efficacy of vitamin D3 supplementation for increasing serum 25-hydroxyvitamin D levels in a randomized controlled trial 2014 · vitamin D3 and calcium carbonate · Healthy non-Hispanic white adults aged 45–75 years | 1.2 g | 1,000 IU | 1 year | — |
| Body mass index, calcium supplementation and risk of colorectal adenomas 2019 · VCPPS calcium carbonate plus vitamin D3 · People with a recently removed colorectal adenoma; sex and age range not specified | 1.2 g | 1,000 IU | 1303 days | — |
| Effect of Calcium and Vitamin D Supplementation With and Without Collagen Peptides on Volumetric and Areal Bone Mineral Density, Bone Geometry and Bone Turnover in Postmenopausal Women With Osteopenia 2022 · Group B · Postmenopausal women with osteopenia | 500 mg | 400 IU | 1 year | — |
| Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial 1998 · Control group · Postmenopausal women with osteoporosis, at least one prevalent vertebral fracture, and low bone mineral density; mean age 68.4 years | 750 mg | 400 IU | 1 year | — |